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1CHAPTER I
INTRODUCTION
Osteoporosis is a debilitating disease characterized by decrease in bone mass and 
deterioration of bone microarchitecture which results in increased fragility and 
susceptibility to fracture (Center & Eisman 1997). It afflicts about 10 million people in 
the US, 80% of whom are women with an additional 44 million people being at the risk 
of developing this disease. Postmenopausal osteoporosis is the most prevalent type of 
osteoporosis and it is predicted that one out of every two American women will have an 
osteoporosis- related fracture in her lifetime (NOF, 2002). For many years, hormone 
replacement therapy (HRT) has been used to prevent osteoporosis as it has been shown to 
improve bone mineral density and lower the risk of fractures in postmenopausal women 
(Komulainen et al. 1998; Hart et al. 1998). Nonetheless, the results of the Women’s
Health Initiative Trial (Rossouw et al. 2002) and the Heart and Estrogen/Progestin
Replacement Study (HERS) (Grady et al. 2002) have clearly indicated that the risks 
associated with HRT outweigh its benefits making it clinically an unacceptable option for 
preventing or treating osteoporosis. Though, several treatment options have been 
approved by the Food and Drug Administration (FDA), the incidence of the disease has 
not declined (Biskobing et al. 2002). Several studies (McCombs et al. 2004; Kotzan et al.
1999) have reported that this may be due to the lack of long-term adherence to treatment.
2This raises the need for therapies that are feasible, inexpensive, with minimal or 
no side effects.
Postmenopausal women are more attracted towards natural alternative therapies 
as they are perceived to have fewer side effects (Heaney 2000). In terms of dietary 
supplements, soy isoflavones have received considerable attention in the prevention and 
treatment of osteoporosis due to their structural similarity to estrogen and their ability in
binding estrogen receptors. However, the effects of soy protein and its isoflavones on 
bone in both women (Potter et al. 1998; Dalais et al. 1998; Ho et al. 2001; Gallagher et 
al. 2000) and ovarian hormone deficient animal models of osteoporosis (Arjmandi et al.
1998; Arjmandi et al. 1996; Anderson et al. 1998; Picherit et al. 2001) are uncertain. 
These differences may be due variations in bioavailability of isoflavones among 
individuals and presence or absence of favorable intestinal microflora (Xu et al. 1995). 
The gut microflora is influenced by compounds known as prebiotics in the diet and play 
an important role in colon cancer prevention, reducing blood glucose and cholesterol, and 
boost the immune system of the host (Nettleton et al. 2005).  For instance, 
fructooligosaccharide (FOS) is classified as a prebiotic and is a non-digestible 
oligosaccharide (Burns & Rowland 2004). The bioavailability and the absorption of soy 
isoflavones e.g., genistin and daidzin, have been reported to increase in the presence of 
FOS in the diet (Tokunaga 2004). Absorption of calcium and magnesium is also 
enhanced by FOS, thereby having the potential to improving skeletal health. In support of 
this notion, Mathey et al., (Mathey et al. 2004) indicated that soy isoflavones in 
combination with FOS prevented bone loss. Therefore, it is reasonable to postulate that 
the combination of soy isoflavones and FOS would be able to reverse bone loss.
3Nonetheless, there are no reports on the extent to which the combination of soy and FOS 
reverses bone loss and, therefore it merits investigation. Therefore in the present research, 
in addition to investigation the dose dependent of soy isoflavones in the reversal of bone 
loss, the efficacy of combining soy with FOS on rebuilding bone in Ovx rats has been 
evaluated  
Research Objectives
The principal objective of this study was to examine the role of soy with varying levels of 
isoflavones in the reversal of bone loss in an ovariectomized rat model of 
postmenopausal osteoporosis. Another objective of this study was to examine the synergy 
between soy protein with normal levels of isoflavones and FOS on reversal of bone loss.   
The specific aims of experiment I were as follows:
1. To examine the dose-dependent effects of soy isoflavones in reversing bone loss by 
assessing bone mineral density (BMD) and bone biomechanical properties by 
utilizing an ovariectomized  rat model of postmenopausal osteoporosis.
 2. To determine the dose-dependent role of soy isoflavones in restoring bone 
structure by assessing trabecular microstructural properties of the proximal tibia 
and the fourth lumbar vertebra.
4The specific aims of experiment II were as follows:
1. To examine the efficacy of Soy, FOS and their combination in reversing  bone loss 
by assessing bone mineral density (BMD) and bone biomechanical properties by 
utilizing an ovariectomized  rat model of postmenopausal osteoporosis. 
 2. To determine the role of Soy, FOS and their combination in restoring bone 
structure by assessing trabecular microstructural properties  of the proximal tibia 
and the fourth lumbar vertebra.
Hypothesis
The central hypothesis of this study was that soy protein with its isoflavones 
reverses bone loss in an ovariectomized (Ovx) rat model of postmenopausal osteoporosis. 
The ancillary hypothesis of this study was that soy isoflavones and FOS exert synergistic
effects in the reversal of bone loss in osteopenic ovx rats.
Format of Dissertation
The experiments are organized in two individual manuscripts for publication. Chapters III 
and IV are written in journal article format using the journal guidelines for Bone, and 
Menopause journals. The other chapters follow the Oklahoma State University format.
5CHAPTER II
REVIEW OF LITERATURE
Osteoporosis is a major health concern as it increases the risk of hip and other 
fragility fractures. It is characterized by decrease in bone mass and deterioration of 
microarchitecture of bone. The World Health Organization defines osteoporosis as 
condition where the BMD is > 2.5 Standard Deviations below the young adult reference 
mean (WHO, 1994). According to National Institutes of Health, osteoporosis is a 
condition of compromised bone strength that leads to increased fracture risk (NIH, 2000).
The National Osteoporosis Foundation estimates that 10 million Americans are already 
afflicted with osteoporosis and another 34 million individuals have low bone mass, 
putting them at risk of osteoporosis-related fractures. The annual expenditure for treating 
osteoporosis- related fractures was $17.5 billion in 2002 (Melton, III 2003) and is 
projected to exceed $60 billion by the year 2020 (Tucci 1998).
The skeleton is a highly specialized and dynamic organ that undergoes continuous 
remodeling (Manolagas 2000). Three main functions of the skeleton include 1)
mechanical support and site of muscle attachment for movement, 2) protection for vital 
organs and bone marrow, and 3) reserve of ions like calcium and phosphorus (Baron 
1993). Anatomically, bone is divided into two distinct types namely trabecular bone and 
compact bone (Martin et al. 1998).  Compact bone (cortical bone) is dense bone found in 
6the shafts of long bones as well as forming a cortex or shell around vertebral bodies and 
other spongy bones. The cortical bone primarily provides the mechanical and protective 
function. Spongy trabecular or cancellous bone is porous bone found in the cuboidal bone 
(e.g., vertebrae), the flat bones, and the ends of the long bones. The trabecular bone 
primarily provides the metabolic function (Baron 2003).  
Mature bone has an outer shell of compact bone known as the cortex, which 
encloses a meshwork of trabecular bone, with interconnecting spaces containing myeloid 
or fatty marrow (Marks & Odgren 2002).  The cortical bone is covered by a periosteal 
membrane, which contains arterioles and capillaries that pierce the cortex, entering the 
medullary canal. These vessels along with larger structures enter one or more nutrient 
canals, which provide the blood supply to bone (Resnick et al. 1995) .
Constituents of bone include collagen, hydroxyapatite, proteoglycans, and 
noncollagenous proteins, bone marrow and water (Baron 2003). Collagen is a structural 
protein and the predominant collagen in bone is type I, which is a rigid, rod-like, 
molecule composed of two alpha chains consisting of repeating amino acids with glycine 
in every third position and a high content of proline and lysine (Martin et al. 1998).  
These chains form a triple helix that is stabilized by the hydroxylation of proline and 
lysine residues by ascorbic acid (Raisz et al. 1998).  The inorganic mineral of bone 
consists of hydroxyapatite crystals that contain carbonate, citrate, sodium, and 
magnesium (Jee W.S.S. 1983).  Proteoglycans’ specific role in bone is not clear; 
however, they may play an important role through their calcium-binding properties 
(Martin et al. 1998). The most abundant noncollagenous protein is osteocalcin, which is 
secreted by the osteoblasts and may play a role in bone mineralization (Martin et al.
71998). Bone marrow lies between the spaces in the trabeculae of all bones (Resnick et al.
1995).  It provides a continuous supply of red blood cells, white blood cells, and platelets 
to meet the tissue’s demands for oxygenation, immunity, and coagulation (Resnick et al.
1995; Martin et al. 1998) .  
The calcified bone matrix is not metabolically inert and there are cellular 
components that are very important for the formation and maintenance of bone (Raisz et 
al. 1998). The major cellular components include osteoclasts, osteoblasts, and osteocytes 
(Raisz et al. 1998). The osteoclasts are the “resorbers” that are closely related to the 
macrophage cells that remove debris or pathologic material throughout the body.  
Osteoblasts or the “formers” are closely related to the fibroblasts, which are cells that 
produce structural molecules in other tissues (Martin et al. 1998).  The osteoclasts are 
responsible for bone resorption and the osteoblasts are responsible for bone formation 
(Raisz 2004).  Another cell type in bone is known as the osteocyte, which is a former 
osteoblast that has become buried in bone and sits in the cavities called lacunae. These 
cells communicate among themselves and osteoblasts through tunnels called canaliculi 
(“canals”) (Martin et al. 1998). The cellular activity is primarily devoted to an orderly 
sequence of bone resorption and formation (Raisz 2004).
The cellular components develop and differentiate through the control provided 
by growth factors, cytokines, and systemic hormones (Manolagas 2000). The exact 
details of this operation are not clear; however, a few mechanisms have been proposed
(Manolagas & Jilka 1995).  These include, 1) growth hormone and cytokines form 
positive and negative feedback loops; 2), some of the same factors influence both 
osteoclasts and osteoblasts; and 3) systemic hormones influence the formation of 
8osteoclasts and osteoblasts through their ability to control the production and/or action of 
local mediators (Manolagas 2000).  
Precursors of osteoclasts are hematopoietic cells of the monocyte/macrophage 
lineage. A large group of cytokines and colony-stimulating factors are involved in 
hematopoiesis and also affect osteoclast development (Schinke T & Karsenty G 2002; 
Manolagas 2000).  These cytokines include interleukins (IL) IL-1, IL-3, IL-6, IL-11, 
tumor necrosis factor (TNF)-, and granulocyte macrophage-colony stimulating factor 
(M-CSF).  The cytokines that inhibit osteoclast development are IL-4, IL-10, IL-18 and 
interferon- (Raisz 2004).
The precursors for osteoblasts are mesenchymal stem cells (Raisz et al. 1998).  
The formation of osteoblasts, osteoblastogenesis, is initiated by bone morphogenetic 
proteins (BMPs) from uncommitted progenitors (Rosen et al. 1996).  Other factors such 
as transforming growth factor  (TGF), platelet-derived growth-factor (PDGF), insulin-
like growth factors (IGFs), and members of the fibroblast growth factor (FGF) family can 
all stimulate osteoblast differentiation (Yanovski et al. 2000; Raisz 2004).  
Bone Modeling and Remodeling
During development and growth, the skeletal size and shape is obtained by the 
removal of old bone and deposition of new bone, a process called modeling (Raisz 2004).  
As the skeletal grows, during childhood and adolescence, bone formation dominates.  
Once the skeleton has reached maturity, regeneration continues via a process known as 
remodeling (Marks & Odgren 2002).  Remodeling is a life long process; however, the 
rate of activity varies depending on the age.  Remodeling results in complete regeneration 
9of bone every 10 years (Manolagas 2000). The purpose of remodeling is thought to repair 
fatigue damage and maintain calcium homeostasis (Martin et al. 1998). At the beginning 
of the third decade of life, there is a steady decrease in bone mass due to the higher rate 
of resorption (Raisz 2004). Bone remodeling becomes uncoupled and the osteoclast 
activity becomes greater than the osteoblast activity resulting in bone loss. This 
phenomenon was described by Albright et al., as early as 1941 (Albright et al. 1941).  
Humoral Regulation of Bone Metabolism
Remodeling can be activated by both systemic and local factors.  One of the main 
systemic factors is the parathyroid hormone (PTH), which is secreted by the parathyroid 
gland.  Parathyroid hormone has a direct effect on bone to regulate bone remodeling and 
enhance the mobilization of calcium from the skeleton (Resnick et al. 1995).  The final 
product of vitamin D, 1,25(OH)2 vitaminD3, is another humoral factor, which regulates 
intestinal mineral absorption and maintains skeletal growth and development (DeLuca & 
Cantorna 2001). However, the exact role it plays in remodeling is unknown.  Calcitonin 
appears to play a small role in regulating bone turnover even though it inhibits bone 
resorption by acting directly on the osteoclasts (Raisz et al. 1998).  Another systemic 
hormone is growth hormone, which increases both circulating and local levels of insulin –
like growth factor–I (IGF-I). Growth hormone (GH) directly stimulates cartilage cell 
proliferation and both hormones increase bone remodeling  (Raisz et al. 1998).  Bone 
cells contain both estrogen and androgen hormone receptors (Raisz et al. 1998).  
Estrogens and androgens are critical for skeletal development and maintenance. Studying 
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the physiology of bone and the mechanisms through which bone remodeling occurs can 
help us better understand the etiology of postmenopausal osteoporosis.
Postmenopausal Osteoporosis
Menopause is defined as the period after 12 months of amenorrhea with no 
pathological reason (NAMS). The postmenopausal period typically occupies one-third of 
a woman’s lifespan (Barrett- Connor, 1993), and currently there are more than 46 million 
postmenopausal women in the U.S. This number is predicted to increase to more than 50 
million by the year 2020 (NAMS, 2000). Postmenopausal osteoporosis was first defined 
by Albright (Albright & Reifenstein 1948) and later expanded by Riggs et al., (Riggs et 
al. 1982) as bone loss caused by the decreased levels of endogenous estrogen.
Postmenopausal osteoporosis is the most common form of osteoporosis and is also 
known as primary osteoporosis. According to the National Osteoporosis Foundation, one 
half of the women will suffer from an osteoporotic fracture in their lifetime (NOF, 2002). 
The annual cost for treating osteoporosis-related fractures in the U.S. is currently 
estimated at $17 billion (Melton, III et al. 2003) and is projected to exceed $60 billion by 
the year 2020 (Tucci 1998). Therefore, osteoporosis-related fractures are enormous 
public health problems with immense socioeconomic implications.
Estrogen deficiency causes an increase in bone turnover with rates of resorption 
exceeding bone formation. The rate of bone loss is about 5% for cancellous bone and 1 to 
3% for cortical bone per year in early postmenopausal women. It is estimated that 
postmenopausal women lose up to 50% of trabecular bone and 30% of cortical bone after 
20 years of menopause. Estrogen protects against bone loss mainly by blocking bone 
11
resorption, (Manolagas & Jilka 1995), but some studies have also shown that it may also 
play a role in bone formation (Chow et al. 1992; Bain  et al. 1993) . The antiresorptive role 
of estrogen is mainly through decreasing osteoclastogenesis, which is the differentiation 
of bone resorbing cells, and the activity of mature osteoclasts. Estrogen also down-
regulates the synthesis of numerous factors that enhance osteoclastogenesis, e.g., IL-1, 
IL-6, M-CSF, TNF-, and prostaglandin (PG) E2 (Schinke T & Karsenty G 2002). These 
effects will be discussed in the section on estrogen and bone.
In addition to preventing bone resorption, estrogen plays an important role in 
calcium absorption in the gut (Gennari et al. 1990) and its reabsorption in the kidney 
(McKane et al. 1995). The presence of estrogen receptors in the intestine has been 
reported and estrogen has been shown to increase intestinal calcium absorption both in 
rats (Arjmandi et al. 1993; Arjmandi  et al. 1994)  and humans (Gennari et al. 1990).
In summary, postmenopausal bone loss occurs by at least two mechanisms, the 
first mechanism is by enhanced osteoclastogenesis which leads to increased bone 
resorption, resulting in an early rapid phase of bone loss (Riggs et al. 1998). This causes 
a rapid influx of calcium from bone into circulation resulting in suppressed parathyroid 
hormone secretion and vitamin D production. During the late phase of menopause, bone 
loss occurs predominantly by a second mechanism, which is due to decreased intestinal
calcium absorption. This decrease in calcium absorption causes secondary 
hyperparathyroidism and increased bone resorption (Riggs et al. 1998). Although 
postmenopausal osteoporosis is a widely researched area, the incidence of the fracture 
has not been reduced considerably and therefore there are still needs for understanding its 
etiology and developing efficacious therapies for postmenopausal osteoporosis.
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The Ovariectomized Rat Model of Postmenopausal Osteoporosis
The FDA guidelines state that in addition to testing for toxicity, therapies used for 
the prevention and treatment of osteoporosis should be tested in preclinical models before 
their use in humans (Thompson et al. 1995). According to those guidelines, osteoporosis 
studies should be conducted using an Ovx rat model to examine whether a test agent is 
effective in preventing or treating osteoporosis. In prevention studies using an Ovx
animal model, treatment should be initiated immediately after ovariectomy. In a bone loss 
reversal study, significant bone loss after ovariectomy should be demonstrated prior to 
initiation of treatment (Thompson et al. 1995).
Ovariectomized rat model is the most commonly used animal model of 
postmenopausal bone loss and has been reported to be an appropriate model to study
cancellous bone changes in humans (Jee & Yao 2001). Additionally, rats are relatively 
inexpensive, easy to handle, changes in bone can be seen in shorter time frame and 
variability in studies can be minimized as genetically specific strains are available 
(Turner 2001). As rats do not experience natural menopause, ovariectomy has been used 
as a method to induce estrogen deficiency in young but skeletally mature rats (Kalu 1991; 
Wronski et al. 1985). Rapid loss of trabecular bone mass and strength occurs shortly after 
ovariectomy and these changes are similar to those that occur in postmenopausal women 
(Westerlind et al. 1997). The rapid bone loss following ovariectomy is caused by 
increased rate of bone turnover, with higher rate of resorption than formation. Other 
similarities between postmenopausal bone loss and ovariectomy-induced osteopenia in 
rats include; 1) higher loss of trabecular than cortical bone; 2) impaired intestinal 
absorption of calcium; and 3) similar effects of treatments such as estrogen, tamoxifen, 
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bisphosphonates, parathyroid hormone, calcitonin and exercise on bone (Kalu 1997).
Laib et al. (2001) reported that cancellous bone volume decreased rapidly by about 40%, 
following ovariectomy and the rate of decrease slowed considerably around  60 days 
post-surgery.  Similar observations were made by Wronski et al., (1985) who reported 
that a two fold decrease in tibial cancellous bone volume occurred following 
ovariectomy.
The use of rat as model of postmenopausal osteoporosis does have some 
limitations. These include; 1) longitudinal bone growth in long bones occurs transiently 
after ovariectomy in rats, however this limitation can be minimized by using 9 to 12 
month-old rats (Wronski & Yen 1991); 2) rats lack or have poorly developed Haversian 
systems (Wronski & Yen 1991); and 3) rats do not experience fragility fractures.
However, these can be assessed by biomechanical testing of the lumbar vertebra and the 
long bones (Kimmel 2002). In spite of these shortcomings, Ovx osteopenic rats are
considered the most appropriate small animal model to study the efficacy of a treatment 
for postmenopausal osteoporosis. Therefore, in the present study, 9-month old female 
Sprague-Dawley rats were used to study the extent to which dietary treatments reverse 
bone loss.
Estrogen and Bone
The fundamental effects of estrogen on the skeleton include; 1) inhibition of bone 
remodeling by halting the activation of new bone remodeling units); 2) suppression of 
bone resorption; and 3) a possible stimulatory effect on bone formation. 
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As discussed earlier, bone loss occurs in estrogen deficiency mainly due to an 
increase in bone remodeling brought about by basic multicellular units (BMUs). BMUs 
are temporary anatomic structures comprising of osteoclasts and osteoblasts (Parfitt 
1994). Loss of estrogen causes a marked increase in osteoclastic precursor cells from 
homatopoietic cells known as colony forming units-granulocytes/macrophages (CFU-
GMs) in the marrow (Jilka et al. 1998). Estrogen also suppresses both osteoclast and 
osteoblast precursors.  Since both osteoblasts and the stromal/osteoblastic cells play an 
important role in osteoclast development, the inhibition of these cells may be a key 
mechanism by which estrogen suppresses bone remodeling (Di Gregorio et al. 2001).  
In addition to its action in reducing osteoblast and osteoclast precursors, estrogen 
plays an important role in osteoclast development, activity, and apoptosis. Receptor 
activator of nuclear factor-kappaB ligand (RANKL) is a nuclear factor that is expressed 
on the surface of bone marrow stromal/osteoblast precursor cells, T-cells, as well as B-
cells (Eghbali-Fatourechi et al. 2003). RANKL is an essential molecule in the 
development of osteoclasts (Lacey et al. 1998). Receptor activator of nuclear factor-
kappa B (RANK) is its cognate receptor that is seen on osteoclast lineage cells (Hsu et al.
1999). Osteoprotegerin (OPG) is the decoy receptor that binds to RANKL and is 
produced by osteoblastic lineage cells (Simonet et al. 1997).  Estrogen suppresses 
RANKL production by osteoblastic, T- and B-cells (Eghbali-Fatourechi et al. 2003) and 
simultaneously increases OPG production (Hofbauer et al. 1999). This results in 
inhibition of bone resorption. The other antiresorptive effects of estrogen are modulated 
through its effects on cytokines that stimulate  bone-resorption, such as IL-1, IL-6, TNF-
, M-CSF, and PGE2. Although several studies have demonstrated the role of these 
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cytokines in resorption of bone, it is seen that multiple cytokines act together in inducing 
bone resorption in the absence of estrogen and seem to have synergistic effects on bone 
resorption. Estrogen also causes an increase in the production of TGF- (Oursler et al.
1991) which has been shown to induce apoptosis of osteoclasts (Hughes et al. 1996).
Estrogen influences all the aspects of osteoclast development, activity, and lifespan, and 
these facts explain why estrogen deficiency results in a marked increase in bone 
resorption. 
From the bone formation point of view, estrogen is found to prolong the lifespan 
of the osteoblast by inhibiting osteoblast apoptosis at the cellular level, thereby increasing 
the function of osteoblast (Kousteni et al. 2001).  Dang et al., (2002) reported that 
estrogen stimulated the differentiation of progenitor cells through the osteoblast lineage 
and not adipocyte lineage, as seen by elevated alkaline phosphatase activity and increased 
nodule formation.  
More recently, it has been reported that estrogen may also act directly on 
osteocytes. Estrogen deficiency has been shown to induce apoptosis of osteocytes 
(Tomkinson et al. 1997) in iliac bone. The apotosis of osteocytes has been shown to be 
inhibited by estrogen in ovariectomized mice (Kousteni et al. 2001). As osteocytes may 
play a role in sensing mechanical loading, the loss of these cells can exacerbate bone loss 
similar that that seen in weightless conditions (Pitsillides et al. 1995). In summary, these 
are some proposed mechanisms by which estrogen influences bone remodeling and plays 
a role in maintaining bone mass. 
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Treatment Options for Postmenopausal Osteoporosis
In general, treatments for postmenopausal osteoporosis are aimed at either 
decreasing bone resorption or increasing bone formation. There have been several 
treatment options that have been approved in the recent years by the Food and Drug 
Administration (FDA), however, their effects on reduction of incidence of fractures 
remains to be seen as the time between starting treatment and assessing its effects on 
bone mass and fracture is several years. Some of the drugs approved by the FDA are 
discussed below.
Bisphosphonates:  Bisphosphonates are class of compounds that are derivatives of 
pyrophosphate. They act by inhibiting hydroxyapatite formation, and thereby decreasing
bone resorption (Akesson 2003). There are several different bisphosphonates that are 
available, however, the major drugs for osteoporosis are alendronate, etidronate, and 
risedronate.  Bisphosphonates interfere with numerous actions of osteoclasts (Russell & 
Rogers 1999) including the disruption of the formation of cytoskeletal actin ring in 
polarized resorbing osteoclasts (Murakami et al. 1995); inhibition of protein tyrosine 
phosphatases (Schmidt et al. 1996); and induction of osteoclast apoptosis (Hughes et al.
1995).
Etidronate was the first bisphosphonate to be tested for osteoporosis (Storm et al.
1990; Watts et al. 1990).  Later a large randomized controlled trial was published with 
the bisphosphonate, alendronate (Liberman et al. 1995). Alendronate was approved by 
the FDA in 1996 and is marketed by Merck Phamaceuticals with the trade name 
Fosamax, for the prevention and treatment of osteoporosis. In a recently published, large 
five-year long clinical trial involving more than 3000 women, alendronate (10 mg/day)
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for 5 years of treatment significantly reduced fracture risk in women with low bone mass 
(Quandt et al. 2005). However, alendronate is associated with numerous side effects
which include nausea, constipation, diarrhea, and abdominal pain (Doggrell 2004). The 
third bisphosphonate used for the treatment and prevention of osteoporosis was
risedronate (actonel™) was approved by the FDA in April 2000. Risedronate has been 
shown to have fewer side effects than alendronate and has also been demonstrated to 
reduce the risk of non-vertebral fracture in women with severe osteoporosis (Adachi et al.
2001). However, currently the data are insufficient to compare fracture rates with 
alendronate and risedronate (The Medical Letter, 2005).
Calcitonin: Calcitonin is a polypeptide hormone made in the C cells in the thyroid 
(Bennet et al., 1984; Raisz et al., 1998).  This hormone acts on the osteoclast by 
inhibiting the proliferation of progenitors as well as the differentiation of committed 
precursors (Price et al., 1980). It is available with the trade name of Miacalcin that is 
usually administered as a nasal spray. Miacalcin (Kaskani et al. 2005) has been shown to 
increase BMD in postmenopausal women, however its effects on fracture risk reduction 
are yet to demonstrated?.  The possible side-effects include runny nose, nose bleeds and 
nose pain and are considered to be mild (Thamsborg et al. 1991; Lyritis et al. 1995). 
Raloxifene: Raloxifene is a benzothiophene derivative that was approved by the FDA in 
December 1997 for the treatment of osteoporosis.  Raloxifene is a new generation SERM 
that has demonstrated estrogen-like effects on the skeleton and cardiovascular system, but 
anti-estrogen effects on the breast and endometrium (Licata et al., 2000, Jordan 2001; 
Setchell 2001). In the MORE (Multiple Outcomes of Raloxifene Evaluation) study
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(Cummings SR, et al., 1998), 7705 postmenopausal women aged 31–80 years with 
osteoporosis, raloxifene increased lumbar spine and femoral neck BMD by 2%–3%, 
reduced the risk of vertebral fractures by 30%–50%, and decreased the incidence of 
breast cancer. However, raloxifene may have potential adverse effects, such as an 
increase in hot flashes, an increase in risk for blood clots in the leg veins and/or the lungs 
(similar to estrogen), leg cramps and fluid retention (Deitcher & Gomes 2004; Vogelvang
et al. 2004). 
Parathyroid Hormone: Parathyroid hormone is an analog of human PTH approved for the 
treatment of osteoporosis in postmenopausal women and men who are at high risk for 
fracture. Depending on the duration of dosing and the mode of administration, PTH can 
either increase bone formation or resorption. Continuous administration leading to 
persistent higher levels of the hormone result in increase bone resorption leading to bone 
loss, whereas, intermittent PTH injections cause a transient peaks in serum hormone 
levels, leading to increased bone formation and BMD. Therefore, intermittent PTH acts 
as an anabolic agent. The studies investigating the role of PTH as a treatment option were 
started as early as 1970s by Reeve et al., (1976) and showed that PTH increased bone 
density in postmenopausal women. The findings of a large two-year, clinical trial 
involving 1637 postmenopausal osteoporotic women who were receiving PTH indicated 
that PTH increased lumbar spine BMD by 9%–13% and there was 65% reduction in 
vertebral fracture risk (Neer et al. 2001). The most common side effects are dizziness and 
leg cramps. Elevations in blood calcium and urine calcium can also occur. The cost of 
administering teriparatide, recombinant human parathyroid hormone (1-34), available by 
the trade name FORTEO®, is $600 per month and the duration of treatment is between 
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18-24 months (Eriksen & Robins 2004). Side effects include marrow fibrosis, tunneling 
resorption, nausea, and headache (Jiang et al. 2003). One of the concerns of PTH use is 
that its safety has not been evaluated beyond two years. 
There are other numerous other agents that are not yet approved by the FDA but 
have undergone or currently undergoing clinical trials for the treatment of osteoporosis.  
These potential treatment options include tibolone , strontium ranelate, OPG, cathepsin K 
inhibitors, etc (Akesson 2003).
In summary, though there are numerous options for the prevention and treatment 
of osteoporosis, they are associated with certain risks. Therefore, there is a need for 
continuous search for an alternative/adjunctive therapy which can reduce the incidence of 
fracture without the side-effects. Among natural compounds, phytoestrogens have shown
immense promise in the prevention and treatment of osteoporosis.  
Phytoestrogens
As the name suggests phytoestrogens are plant estrogen-like compounds that may 
have beneficial effects on the cardiovascular system and may help in alleviating some of 
the symptoms that are attributed to menopause such as osteoporosis and breast cancer 
(Wroblewski & Cooke 2000). Isoflavones, lignans and coumestans are the major types of 
phytoestrogens (Brezinski & Debi 1999; Knight & Eden 1996). Common and significant 
edible source of isoflavones are soybeans and to a lesser extent other legumes such as 
chick peas and black-eyed peas. The richest source of lignans, are, oilseed and cereals.
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Broccoli and alfalfa sprouts are rich in dietary coumestans. Coumestans are more potent 
in their estrogenic activity than isoflavones (NAMS, 2000). Phytoestrogens are 
heterocyclic compounds that have structural similarities to estrogenic steroids (Murkies et 
al. 1998).
Plant isoflavones and lignans are converted to heterocyclic phenols in the gut and 
these compounds are similar in structure to estrogen and they exhibit weak estrogenic 
properties (Murkies et al. 1998). Phytoestrogens have varying effects on different tissues 
and various types of phytoestrogens have varying affinities to estrogen receptors 
(Anderson et al. 1995).
Phytoestrogens have shown both estrogenic and anti-estrogenic properties. They 
are estrogenic because they have a tendency to bind to estrogen receptors (Miksicek 
1993). They are anti-estrogenic because, unlike estrogen, they inhibit the activity of 
aromatase and the proliferation of the breast cells (Morito et al. 2001).  In addition to 
acting by binding to estrogen receptors, phytoestrogens may impart additional health 
benefits by acting as anti-oxidants. This conclusion is based on the oxidative resistance of 
the LDL-cholesterol obtained from participants consuming high levels of phytoestrogens 
(Tikkanen et al. 1998) .
Scientists in various countries are beginning to explore the health benefits of 
numerous phytoestrogens in chronic diseases including cancer, heart disease and 
osteoporosis. The incidence of chronic diseases, e.g. cardiovascular disease, cancer, 
osteoporosis and stroke is much less in countries consuming high amounts of soy when 
compared with countries that do not traditionally consume soy (Clarkson 2000). Japanese 
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women are found to have significantly lower rates of deaths related to cardiovascular 
disease, osteoporosis and cancers (Boring et al. 1994) . 
Soy Isoflavones
The three major isoflavones that are present in soy are genistein, daidzein, and 
glycetein (see figure 1 for structures). One gram of soy contains about 1 to 3 mg of 
diadzin, genistin, glycetin and their corresponding glucosides (Barnes & Messina, 1991). 
Genistein and diadzein comprise the major portion of isoflavones in soy and have been 
shown to bind to estrogen receptors, a property explained by their structural similarity 
with estrogens (Knight & Eden 1996b). The phenolic ring is the essential structural 
element that enables these compounds to bind to estrogen receptors (Setchell 1998). The 
findings by Kuiper et al. (Kuiper et al. 1998) showed that the binding affinity of genistein 
to ER- was about 20 times greater than binding ER-. ER- is expressed more in non-
reproductive tissue, such as bone and the vascular system. This may explain some of the 
bone-protective effects of soy isoflavones without the side-effects on uterine tissue.
Figure 1: Major soy isoflavones, genistein, diadzein and glycetein.
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Isoflavones are conjugated substances, when hydrolysed by -glucosidases in the 
jejunum, release bioactive aglycones, daidzein and genistein. These aglycones have been
shown to have affinity for estrogen receptors and have other non-hormonal effects on the 
cellular mechanisms (Setchell 1998). By looking at the pharmacokinetics of soy 
isoflavones, it is seen that maintaining high steady state of plasma concentrations can be 
maintained only by the daily intake of phytoestrogens throughout the day (Setchell 2000).
Since soy isoflavones can be easily incorporated into daily diet in various forms, it is 
relatively easy to maintain the plasma concentrations of isoflavones and their metabolites. 
Thus, soy isoflavones can be used as a feasible and inexpensive adjunctive/alternative 
therapy for osteoporosis. The following sections will discuss the efficacy of soy 
isoflavones in prevention and reversal of bone loss and their mechanisms of action.
Soy and Bone – Animal Studies
The role of soy isoflavones in modulating bone have been examined using various 
animal models including ovariectomized rats (Arjmandi et al. 1996; Arjmandi et al.
1998), mice (Fonseca & Ward 2004) and cynomolgus monkeys (Register et al. 2003). 
Arjmandi et al., (Arjmandi et al. 1996) were one of the first groups to report that soy 
protein-based diet was efficacious in preventing bone loss  as it attenuated loss of 
vertebral bone density and positively modulated biomarkers of bone formation and 
resorption. In a follow up study (Arjmandi et al. 1998), the same investigators examined
whether soy protein or its isoflavones are responsible for the bone protective effects of 
soy.  Ovx rats were fed soy protein based diet with normal isoflavone or soy protein 
based-diet deplete of isoflavones. The findings of that study indicated that rats that 
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received soy with normal isoflavones content had significantly greater femoral bone 
density than rats that received isoflavone-deplete soy diet. These findings were similar to 
those of Picherit et al., (Picherit et al. 2001) who reported that isoflavones prevent bone 
loss in Ovx rats by increasing bone formation and reducing bone resorption. Blum et al., 
(2003) also reported the bone-sparing effects of soy isoflavones indicated by increased 
endocortical and cancellous bone formation as measured by histomorphometric analyses
Although prevention is better than cure, a large number of postmenopausal 
women are already suffering from osteoporosis, and it is desirable to have a treatment 
option that would reverse bone loss with minimum or no side effects. Therefore, the role 
of soy isoflavones in the reversal of bone loss has also been examined and there have 
been conflicting results. Isoflavones have shown to have modest effects on the reversal of 
the ovarian hormone deficiency-induced bone loss (Arjmandi et al. 1998). In contrast to 
this study, Picherit et al., (2001) indicated that although soy isoflavones prevent bone 
loss, they do not reverse bone loss in Ovx rats. Similar observations were also made in 
ovariectomized monkeys (Lees & Ginn 1998; Register et al. 2003). The differences in 
these findings may be due to the variations in the age of the animals, duration of the 
study, and the dose of isoflavones used in these studies. This raises the need for studies 
that are appropriately powered using relevant animal models with a good experimental 
design.
Soy and Bone – Human Studies
A few clinical studies (Arjmandi et al. 2005; Potter et al. 1998; Alekel et al.
2000) have examined the effects of soy isoflavones on bone mineral density and the 
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results of these studies are inconclusive. One of the earlier studies were conducted by 
Potter et al., (1998) in which 66 postmenopausal women receiving 90 mg of isoflavones 
with 40 g soy protein had a significant increase in spine, but not hip BMD after six 
months of treatment. In a similar study by Alekel et al. (2000) of perimenopausal women 
receiving 80 mg isoflavones/day, isoflavones prevented the loss of  lumbar spine BMD 
or BMC, whereas, significant losses in BMD and BMC occurred in the control group.
One year supplementation of 80 mg/d isoflavones have been shown to increase trochanter 
BMC, but not BMD, in postmenopausal Chinese women with low initial bone mass 
(Chen et al. 2003). The findings of a recently published one-year study by Arjmandi et 
al., (2005) indicated that supplementation of 25 g soy protein with 60 mg isoflavones 
positively modulated markers of bone formation, but is unable to prevent the loss of 
lumbar and whole body BMD in postmenopausal women.
The effects of soy supplementation on biomarkers of bone formation and 
resorption are also contradictory. In a study by Alekel et al. (2000), the positive effects of 
soy supplementation by changes in serum bone-specific alkaline phosphatase activity, a 
marker of bone formation, or urinary N-telopeptide (NTX), a marker of bone resorption, 
as these markers were not affected by treatment. Similar observations were made by 
Wangen et al (2000), where soy isoflavones had minimal effects on bone biomarkers. In a 
short term clinical trial by Arjmandi et al. (2001), consumption of 40 g soy protein with
90 mg isoflavones daily significantly reduced urinary Dpd excretion, a specific marker of 
bone resorption and concurrently increased serum IGF-I concentrations in 
postmenopausal women. These conflicting reports may be due to the fact that 
biochemical markers of bone turnover are highly variable and studies assessing these 
25
should have large sample sizes (Weaver & Cheong 2005). Bone is a tissue which is 
undergoing constant remodeling and to observe treatment effects on bone studies have to 
be long enough to accommodate several remodeling cycles (Weaver & Cheong 2005). 
Therefore, there is a need for long-term, large clinical studies to confirm the bone 
protective effects of soy isoflavones.
Mechanism of Action of Soy Isoflavones on Bone
Several mechanisms have been proposed by which soy isoflavones exert 
beneficial effects on bone including their structural similarity with estrogen.  In the early 
1970s, Shutt and Cox (1972) determined that phytoestrogens have a binding affinity to 
estrogen receptors and more recently Kuiper et al., (1997) demonstrated that genistein has 
a particular binding affinity for estrogen receptor-, (Kuiper et al. 1998). Thus, the 
binding of isoflavones to estrogen receptor- is postulated as the possible mechanism by 
which isoflavones modulate bone (Burke et al. 2000). The binding affinity of isoflavones 
to ER-, but not ER- (Kuiper et al. 1997), causes beneficial effects on bone without the 
undesirable side-effects on breast and uterine tissue. Estrogen independent effects of 
isoflavones have also been reported (Akiyama et al. 1987; Blair et al. 1996). An in vitro
study by Akiyama et al. (1987), showed that genistein inhibits the tyrosine-specific 
protein kinase activity of the epidermal growth factor (EGF) receptor and therefore,
results in decreased osteoclastic protein synthesis (Blair et al. 1996). The effect of soy on 
calcium absorption, in part, may protect against bone loss as reported by Arjmandi et al.
(2002), where similar to estrogen, soy- treated Ovx rats experienced enhanced intestinal 
calcium absorption. Additionally, soy supplementation has been reported to increase the 
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circulating and mRNA levels of insulin-like growth factor-1 (IGF-1) in postmenopausal 
women (Arjmandi B.H. et al. 2003) and Ovx rats (Arjmandi et al. 1998), respectively. 
Several studies (Langlois et al. 1998; Bauer et al. 1997) have reported the close 
correlation between circulating levels of IGF-1 and BMD  and isoflavones may positively 
modulate bone via the IGF-1 dependent pathway. Soy isoflavones have also been shown 
to exhibit antioxidant properties by inhibiting the production of hydrogen peroxide and 
activating antioxidant enzymes such as catalase, superoxide dismutase, glutathione 
peroxidase, and glutathione reductase (Wei et al. 1995). Antioxidants prevent oxidative 
damage and thereby prevent bone resorption and stimulate bone formation (Basu et al.
2001; McBride J 1999). Though these are some plausible ways by which soy isoflavones 
may exhibit bone protective effects, their mechanism of action remains to be clarified.
Fructooligosaccharides
Traditionally, the main functions of colon are described as water and electrolyte 
absorption, and storage and excretion of waste (Marfarlane & McBain 1999). It also 
plays an important role in nutrient absorption, which is mainly due to the metabolic 
activities of intestinal microflora (Berg 1996). Lactobacillus and Bifidobacterium species 
are the two important types of bacteria that constitute the intestinal microflora (Reid & 
Burton 2002). The gastrointestinal tract is a dynamic ecosystem where these microflora 
ferment the foods and their components that are present in the colon of the host. The 
composition and activities of these bacteria can be modified by diet to enhance their 
beneficial effects. These beneficial effects include 1) energy generation by fermenting the 
carbohydrates and proteins (Cummings & Macfarlane 1991); 2) synthesis of certain 
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vitamins such as vitamin B and K (Berg 1996); 3) production of short chain fatty acids, 
that lower the pH of the colon and increase water absorption (Gibson & Roberfroid 
1995); 4) synthesize antimicrobial compounds (Yildirim & Johnson 1998); and 5) 
enhancement of gut barrier function as these microorganisms compete with disease 
causing pathogens for adhesion receptors in the intestinal mucosa and thereby improve 
host’s immunity (Cebra 1999; Cunningham-Rundles & Lin 1998). 
Certain dietary components stimulate the growth of these beneficial bacteria and 
are defined as prebiotics. These include, FOS and inulin, which are short chain 
carbohydrates that are resistant to digestion in the upper GI tract by human enzymes 
(Gibson & Roberfroid 1995).  FOS is fermented in the colon by the intestinal microflora 
to short chain fatty acids (SCFAs), hydrogen, and carbon dioxide (Cummings & 
Macfarlane 1991). Wiechmann (1996) has reported an increase in a calcium binding 
receptor, recoverin, during the SCFA-induced differentiation in cells. Additionally, the 
absorption of calcium and magnesium are shown to increase in rats that are fed FOS
(Ohta et al. 1994) .
In terms of soy isoflavones, as mentioned earlier, a study by Mathey et al., (2004) 
demonstrated the efficacy of soy isoflavones is enhanced in the presence of FOS in 
preventing bone loss in Ovx rats. The beneficial effects of this combination may be due 
to the increased bioavailability of the isoflavones by FOS. The primary isoflavones,
genistein and diadzein commonly occur as glyconated forms and the glycosidic bonds 
have to be hydrolyzed by an enzyme, -glucosidase before they can become bioactive
(Setchell 1998). The activity of -glucosidase increases with FOS administration and 
thereby promotes the bioavailability of isoflavones. Additionally, equol, a metabolite of 
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diadzein is synthesized by intestinal bacteria and FOS increases the growth of these 
beneficial bacteria (Setchell 1998). In summary, in addition to the benefits of either soy 
or FOS alone on bone, these may be some of the mechanisms by which FOS in 
combination with soy exerts beneficial effects in reversal of bone loss. Therefore, the 
efficacy of this combination in the reversal of bone loss merits investigation.
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Abstract
Soy protein is reported to prevent bone loss in both women and rat models of 
osteoporosis. However, the role of soy isoflavones on the trabecular microarchitectural 
properties needs to be explored. In the present study, we examined whether soy protein 
with graded doses of isoflavones reverses loss of bone mineral density (BMD), bone 
mineral content (BMC), and trabecular microstructure in an ovariectomized (Ovx) 
osteopenic rat model. Seventy-eight 9-m old female Sprague-Dawley rats were either 
sham-operated (Sham; 1 group) or Ovx (5 groups) and fed a semi-purified casein-based 
diet. After 90 days the occurrence of bone loss was confirmed using dual energy x-ray 
absorptiometry. Thereafter, rats were assigned to the following treatments: Sham, Ovx 
(control), Ovx+17-estradiol (E2; 10 µg/kg body wt. twice per wk), Ovx + soy protein 
depleted of isoflavones (Soy-; 0.06 mg isoflavones/g protein), Ovx + soy protein with 
normal isoflavone content (Soy; 3.55 mg isoflavones/g protein), and Ovx + soy protein 
enriched isoflavones (Soy+; 7.10 mg isoflavones/g protein). After 125 days of treatment, 
rats were euthanized and tissues were collected for the assessment of BMD and BMC, 
and tibial and 4th lumbar trabecular micro-architectural properties via x-ray 
microcomputed tomography. Soy significantly increased tibial BMC and BMD by 10 % 
and 4.5% in comparison with Ovx control, whereas the effects of Soy-, Soy+ and E2 were 
less pronounced. All of the soy-based diets, irrespective of their isoflavone content, had a 
modest effect on the lumbar BMD. However, only the Soy+ diet positively affected the 
tibial architectural properties including trabecular thickness, separation, and number. 
None of the treatments had any effect on trabecular microarchitectural properties of the 
fourth lumbar vertebra. In summary, our findings suggest that isoflavones may exert a 
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biphasic effect on tibial BMD, and higher doses of isoflavones may be required to reverse 
the loss of tibial microstructural properties.
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Introduction
Among the edible plants, soybeans are the richest source of isoflavones which 
may improve bone health. Lately, certain estrogen-like compounds of plant origin, such 
as soy isoflavones, have been characterized as naturally occurring selective estrogen 
receptor modulators (SERMs) with similar beneficial effects to raloxifene on bone [1-3]. 
Hence, similar to synthetic SERMs, soy isoflavones have been suggested to exert the 
beneficial effects of estrogen without its side effects [2]. However, the effects of soy 
protein and its isoflavones on bone in both women [4-7] and ovarian hormone deficient 
animal models of osteoporosis [8-11] are uncertain. 
Decreased bone mass is only one of the many factors jeopardizing bone integrity, 
resulting in reduced bone strength and increased susceptibility to fractures. Other 
important factors that influence bone health include architectural arrangement, presence 
or absence of microfractures, and abnormalities in bone matrix or mineralization [12-14]. 
In support of this notion, emerging data [15,16] raise the issue of whether treatment-
induced changes in BMD are predictive of fracture risk reduction. For instance, a study 
by Sarkar et al. [15] showed that raloxifene reduced the risk of fracture without a 
corresponding increase in BMD. Findings from a meta analysis by Cummings et al. [16]
also indicated that assessing BMD alone is not adequate and suggested that other 
parameters, not measured by standard densitometry, are necessary to be evaluated. In 
terms of bone density, there was significant overlap between the subjects who have 
experienced osteoporotic-related fractures and those who remained fracture free [17]. 
These studies [15,16] strongly suggest a need for assessment of other parameters such as 
bone quality and trabecular microstructural properties to predict future fractures.
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Because the trabecular architecture is anisotropic [18], its most accurate 
evaluation requires 3-dimensional (D) imaging. Although histomorphometry has been in 
use for a number of years, it provides only limited 2-D information about trabecular 
structure. Trabecular integrity is compromised as a result of aging and estrogen 
deficiency [17]. Therefore, the aim of present study was to examine the ability of graded 
doses of isoflavones in the context of soy protein to improve the 3-D architecture of 
trabeculae lost due to ovariectomy.  
Materials and methods
Animal care, diets and bone density assessment
Seventy-eight 9-month old female Sprague-Dawley rats (Harlan; Indianapolis,
IN) were housed in an environmentally controlled laboratory upon arrival and 
acclimatized for five days. The animals were either ovariectomized (Ovx; 5 groups, 
N=12-13) or sham-operated (Sham; 1 group N=13) and were fed AIN-93M (Teklad 
Madison, WI) diet for 3 months. Rats were pair-fed to the average food intake of Sham 
group and had free access to deionized water. Food intake was recorded every three days 
and body weights were measured weekly. After bone loss was confirmed using a dual 
energy x-ray absorptiometry (DXA;QDR-4500A Elite; Hologic, Waltham, MA), rats 
were assigned to following treatments: Sham, Ovx (control), Ovx + 17-estradiol (E2; 10 
µg E2/kg body wt. twice per wk subcutaneously), Ovx + soy protein depleted of 
isoflavones (Soy-; 0.06 mg isoflavones/g protein), Ovx + soy protein with normal 
isoflavone content (Soy; 3.55 mg isoflavones/g protein), and Ovx + soy protein enriched 
isoflavones (Soy+; 7.10 mg isoflavones/g protein). The diets were isonitrogenous and 
isocaloric experimental powdered diets. Rats in the Sham, Ovx, and E2 groups were fed 
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casein-based diet that contained 0.4% calcium, 0.3% phosphorus, and 0.195 nmol/g 
vitamin D3 and the rats in the soy groups were fed a similar diet in which casein was 
replaced with soy protein isolate (22.7 g/100 g diet; The Solae Company, St. Louis, MO). 
The calcium and phosphorus levels were adjusted to the casein-based diet (Table 1). The 
calcium and phosphorus contents of proteins were 0.015 and 0.743 g/100 g casein, 
respectively and 0.342 and 0.826 g/100 g soy protein, respectively. The proximate 
analyses of the diets confirmed that the diets were similar in macronutrients, calcium and 
phosphorus contents. 
All conditions and handling of animals were approved by the Institutional Animal 
Care and Use Committee. At the end of a 125-day treatment period, rats were 
anesthetized with a mixture of ketamine and xylazine (70 mg and 3 mg/kg body weight, 
respectively) to measure whole body BMD and BMC using DXA and then sacrificed and 
bone specimens were collected.  
The BMD and BMC of the tibiae, and 4th lumbar vertebrae were measured using DXA 
equipped with appropriate software for bone density assessment in small laboratory 
animals as reported elsewhere [19]. 
Microcomputed tomography (µCT) analysis of tibia and 4th lumbar vertebra
The treatment effect on trabecular structure of the right tibial metaphysis and 4th
lumbar vertebra were evaluated using µCT 40 scanner (Scanco Medical, Switzerland). 
All specimens obtained at sacrifice had been frozen at -20°C until the time of scanning. 
The tibia was scanned from the proximal growth plate in the distal direction (16 
µm/slice). This region included 350 images obtained from each tibia using 1024 x 1024 
35
matrix resulting in an isotropic voxel resolution of 22 µm3 [20]. An integration time of 70 
milliseconds per projection was used, with a rotational step of 0.36 degrees resulting in a 
total acquisition time of 150 minutes/sample. The volume of interest (VOI) was selected 
as a region twenty five slices away from the growth plate at the proximal end of the tibia 
to 125 slices. The 3D images were also obtained for visualization and display.
 Lumbar vertebra were scanned from the caudal to the dorsal end (530 
slices;16µm/slice). This region included 530 images obtained from each vertebra using 
the same isotropic voxel resolution and integration time as described with the tibia. The 
VOI selected 25 slices away from the appearance of the growth plate at each end of the 
vertebral body resulted in approximately 300 slices. Bone morphometric parameters 
including bone volume over total volume (BV/TV), trabecular number (Tb.N.), 
separation (Tb.Sp.), thickness (Tb.Th.), connectivity density, and structure model index 
(SMI) were obtained by analyzing VOI. The operator conducting the scan analysis was 
blinded to the treatments associated with the specimen.
Statistical analyses
The data analysis involved estimation of means and SEM using the Statistical 
Analysis System (SAS) version 8.2 (Cary, NC). Analysis of variance (ANOVA) was 
performed to determine whether there were statistically significant (P < 0.05) differences 
among the groups. When ANOVA indicated any significant differences among the 
means, Fisher’s Least Significant Difference follow-up multiple comparison test was 
used to determine which means were significantly different (P < 0.05). 
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Results
Body and organ weights
In spite of pair feeding the animals, the final body weights of Ovx controls were 
significantly higher than the sham animals (Table 2). Estrogen completely prevented the 
Ovx-induced weight gain as the mean weight of rats in the E2 group was not different 
from that of the Sham. While Soy+ had an intermediary effect in preventing the weight 
gain due to Ovx, Soy and Soy- had no such effect on body weight. As expected, Ovx 
caused atrophy of uterine tissue, indicating the success of the surgical procedure and 
administering E2 significantly increased the uterine weight compared to Ovx controls 
(Table 2).  
Bone mineral content and density 
There were no differences in the whole body BMC among any of the treatment 
groups; however, ovariectomy significantly lowered the whole body BMD (Table 3). 
Whereas, Soy increased the tibial BMC by 10.3%, bringing it up to the level of sham, 
Soy-, Soy+ and E2 had no such an effect. Soy also increased tibial BMD by 4.5%, which 
was significantly higher than Ovx controls, but was still lower than mean tibial BMD of 
sham animals. The other treatments were not able to reverse tibial loss as indicated by 
BMD due to Ovx. Ovariectomized animals also experienced loss of lumbar BMC and 
BMD. While none of the treatments were able to influence fourth lumbar BMC, E2 was 
able to increase the 4th lumbar BMD but not to the level of sham animals. The Soy-, Soy, 
and Soy+ tended to have a positive effect on 4th lumbar BMD, but the values were not 
statistically different from Ovx controls. 
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µCT Analysis
Three-dimensional images of proximal tibia showed differences in trabecular 
architecture among the various treatment groups as represented in Figs. 1A-1F and Fig. 2. 
Analysis of data indicated that Ovx decreased proximal tibial and lumbar trabecular 
BV/TV (Fig. 1A) by 30% when compared to the sham-operated animals. Ovx decreased 
Tb.N. (Fig. 1B), but increased Tb.Th. (Fig. 1C) and Tb.Sp. (Fig. 1D) in the proximal 
tibia. In contrast, Tb.Th. in the vertebra was decreased in response to ovariectomy. Tibial 
and vertebral Tb. N. (1B) were decreased by 25% and 20%, respectively. Tb.Sp. (Fig. 
1D) was increased in both bones by 26% compared to the sham animals. Ovx also 
significantly reduced connectivity density (Fig. 1F) in the tibia and vertebra. 
Interestingly, SMI, which quantifies the pattern of trabeculae as either more rod- or plate-
like was 1.42 in the sham group (Fig. 1E), while in the Ovx animals there was a shift to 
less favorable rod-like (i.e. SMI=2.4) trabecular morphology. There were no significant 
differences in the SMI values of the 4th lumbar vertebrae as a result of Ovx.
Neither the soy-based diets nor E2 were able to restore trabecular bone volume or 
thickness in these osteopenic rats. E2 administration reduced the Tb.Th. of the tibia in 
comparison with all the other groups including sham (Fig. 1C). Soy-, Soy+ and E2 further 
reduced Tb.Th. of the vertebra to the levels below the Ovx control animals. Soy+ and E2
treatments were able to restore Tb.Sp. and Tb.N. to sham levels (Fig. 1 B and D) in the 
tibia but not in the vertebra. In the lumbar bone, Tb.Sp. was significantly higher in the 
Soy- and E2 groups, but not in the Ovx, Soy and Soy+. None of the soy-based diets or E2
were able to improve the ratio of rods and plates or connectivity density (Fig. 1 E and F) 
induced by Ovx in both the bones analyzed. The increase in trabecular number and 
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decrease trabecular seperation indicate some beneficial effects of Soy+ in restoring 
microarchitectural properties in the tibia. The effects of soy were less pronounced in the 
lumbar vertebra.
Discussion
In agreement with our previous observations [9,21] the excess body weight gain 
due to Ovx was completely prevented by E2 administration as expected [21]. Similar to 
E2, Soy+ was able to significantly reduce the Ovx-induced body weight gain by 6%, 
indicating that isoflavones at certain dosage behave like estrogen at least in terms of 
influencing body weight. Our earlier findings [8] and those of Blum et al. [22] also 
support that soy isoflavones are able to prevent excess body weight gain in ovarian 
hormone deficiency. 
Estrogen and isoflavones may be involved directly in energy metabolism by binding 
to estrogen receptors within the abdominal, subcutaneous, and brown fat pads [23,24]. In 
humans, it has been shown that soy supplementation results in an increase in hip lean 
mass indicating a role for soy isoflavones in promoting lean mass and reducing adipose 
tissue [25]. In the present study, the observed reductions in body weight may be due to 
changes in energy metabolic pathways as all rats consumed similar amounts of food. 
Isoflavones may also influence body composition by altering serum levels of leptin, a 
hormone that regulates energy expenditure as suggested by our earlier animal study [26].
In regards to bone, an earlier study [27] by our laboratory demonstrated that soy 
protein had a slight reversal effect on femoral bone loss in a young mature (i.e. four month 
old) osteopenic rat model. The rats in the present study were three times older than that of the 
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earlier study (twelve- vs. four-month old at the initiation of treatments), hence the response to 
treatment may differ when compared to younger rats. As Kalu et al. [28] stated, the changes 
in skeletal characteristics of this age rat (i.e. 12 month-old)  when ovariectomized are 
primarily due to ovarian hormone deficiency, and are uncomplicated by continued rapid bone 
growth and age-related bone loss due to other factors. Hence, the observations of the present 
study may be similar to that which occurs in postmenopausal women who have already 
experienced significant bone loss [29].
In this study, we have determined the effects of soy isoflavones on different bone 
sites including tibia and lumbar vertebra. Bone loss due to Ovx occurred at all sites with 
varying degrees. Similar to our earlier observations [27], the findings of this study indicate 
a modest bone modulating effects of soy and its isoflavones in these older rats. In our 
earlier observations soy diets were somewhat effective in reversing the femoral but not 
the fourth lumbar bone-density loss. In that study, we speculated that the bone protective 
effect of soy was due to its isoflavone content and its ability to increase bone insulin-like 
growth factor-1 mRNA transcripts which is known to correlate with both bone mineral 
density and the rate of bone formation [30,31]. In the present study, although none of the 
treatments were able to reverse whole body BMD, tibial BMD was significantly 
increased in the Soy group by 4.5% in comparison with Ovx controls. Soy-, Soy+, and E2
had an intermediary effect, in that tibial BMD was increased, but not to that of the sham 
level. Therefore, our data suggest that in order to examine the effects of soy or its 
isoflavones, as therapeutic agents, it may be necessary to assess various bone sites to 
determine their efficacy in reversing bone loss. However, our findings were in contrast to 
those of Picherit et al., [32] who reported that isoflavones were not able to reverse bone 
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loss in osteopenic rats. In that study [32], isoflavones were not fed in the context of soy 
protein and the treatment period was shorter than the present study (84 vs. 125 days). 
These differences in the study design and the protein sources may explain the 
discrepancies in the results. In terms of tibial BMD, our observations coincide with the 
findings of Anderson et al. [33] who reported that soy isoflavones have a biphasic effect, 
where too little or too much would not be ideal. In terms of BMC, Soy was able to 
completely reverse the loss in the tibia. Alekel and colleagues [34] have made similar 
observations in premenopausal women where soy with normal isoflavone content had a 
significant effect on percent change in BMC, but not on percent change in BMD. 
However, in the present study, the effect on 4th lumbar vertebrae was less pronounced. 
These findings are in contrast to those of human studies [4,34]which have shown soy 
with isoflavones improves 4th lumbar BMD and BMC more so than at other sites. At this 
point, we cannot offer a reasonable explanation for our findings in this study. 
BMD has been described as only a surrogate measure of bone strength [35] and 
additional parameters such as trabecular micro-architectural properties are necessary to 
evaluate the true impact of a treatment on quality of trabecular bone. Although low bone 
mass is a major risk factor for fracture [36], the preservation of trabecular bone 
architecture significantly contributes to bone strength and may reduce fracture risk beyond 
BMD and BMC as demonstrated by a number of studies which have reported close 
correlations between microstructural properties and biomechanical strength of bone [37-
39].  Since trabecular bone is more readily lost due to Ovx in this animal model [40], it is 
reasonable to assume that the trabeculae would be more responsive to treatment. As 
shown by other investigators [41,42], µCT evaluation of the trabecular bone in the 
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metaphyseal region of tibia and the fourth lumbar vertebra indicated that Ovx significantly 
reduced BV/TV and Tb.N., while increasing Tb.Sp. Restoration of Tb.N. is an important 
step towards improving bone strength and our results showed that Soy+ and E2 were able 
to reverse the detrimental effects of Ovx in the tibia. This increase in Tb.N. may be a 
reason for seeing a decrease in Tb.Sp. A number of studies [42,43] have reported a 
decrease in Tb.Th. following Ovx. In contrast to these findings [39,42,43], in the present 
study Tb.Th. of the tibia was increased in the Ovx animals. We speculate that this 
discrepancy may be due to the age of animals and the number of days post Ovx. Laib et al. 
[44] had also shown that Tb.Th. decreased 35 days after Ovx, but as Ovx period continued 
there was a gradual increase in Tb.Th. Our findings and those of Laib et al. [44] are in 
agreement with the observations made in osteoporotic women, where the number of 
trabeculae is reduced while their thickness is increased [45,46]. As it has been suggested 
[47], this increase in trabecular thickness may be a compensatory mechanism to make up 
for the lost trabecular connectivity. 
SMI of 0 and 3 represent bone that consists purely of plate- or rod-like structures, 
respectively. Values observed in the sham group represent bone with even distribution of  
plate like- and rod like- structures [44]. After ovariectomy the trabeculae become more 
rod-like as demonstrated by the increase in SMI. Although Soy+ in the present study had 
positive effects on the Tb.N. and Tb.Sp. of tibia, none of the treatments including E2, were 
able to restore trabecular bone completely. These findings are in agreement to those of 
other investigators [44] who were unable to observe restoration of trabecular structure 
after its deterioration has occurred, emphasizing the need for prevention of trabecular bone 
loss.
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In the present study, we did not observe any beneficial effects of treatments on 
lumbar microarchitectural properties. Our findings are in agreement with those of Kinney 
et al., [47] who reported that responses to treatment, e.g. estrogen were weaker in the 
vertebrae than tibiae. Further studies are needed to evaluate whether higher doses of 
isoflavones are needed to restore the lumbar microstructural properties. 
Based on the results of the present study, soy protein and its isoflavones appear to 
have a modest beneficial effect in established osteoporosis as evident by improvements in 
tibial BMC and BMD and certain structural parameters. The bone modulating effects of 
soy isoflavone may be, in part, due to increased bone formation, decreased bone 
resorption or both. Several studies suggest [22,48] that soy isoflavones, induce bone 
formation based on at least three lines of evidence: 1) stimulation of activity, proliferation, 
and differentiation in cells of osteoblast lineage [49-51]; 2) protection of osteoblasts from 
apoptosis [49,50]; and 3) enhancement of bone formation rate as assessed by bone 
histomorphometry [22,48]. Additionally, our recent data clearly indicate that isoflavones 
in the context of soy protein increases mRNA levels of bone specific alkaline phosphatase, 
an indicator of osteoblastic activity, and several of bone matrix proteins including type I 
collagen and osteocalcin in ovx rats [52]. Regarding bone resorption, in vitro studies have 
also indicated that soy isoflavones suppress osteoclast activity [53-55]. We have also 
demonstrated the antiresorptive effects of soy supplementation in postmenopausal women 
not on HRT [56]. However, from the review of existing literature it is too early to state 
that soy protein or its isoflavones should be supplemented to prevent or reverse bone loss 
induced by ovarian hormone deficiency.
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Table 1: Diet Composition
Ingredient Control Diet 
(g/100g)
Soy Diet 
(g/100g)
Soy protein (normal isoflavones)1 22.70
Casein2 22.70
Corn Starch 20.00 20.00
Sucrose 41.76 41.76
Cellulose4 5.60 5.60
Corn Oil 5.70 5.70
Mineral mix, Ca-P deficient (TD 
79055)5
1.34 1.34
Vitamin mix (TD 40060)6 1.0 1.0
Calcium carbonate CaCO3 1.16 1.03
Sodium phosphate monobasic 
NaH2PO4.H2O
0.388 0.388
Potassium Phosphate, monobasic 0.238 0.238
Potassium Citrate, monohydrate 0.090 0.090
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1
 Teklad diet #88190 (Harlan Teklad, Madison, WI).
2
 Soy protein isolate obtained from The Solae Company (St. Louis, MO).
3
 Alphacel obtained from ICN Biochemicals (Costa Mesa, CA).
4
 Vitamin mixture (g/kg diet; TD 40060) obtained from Harlan Teklad (Madison, WI):  p-aminobenzoic acid, 0.1101; 
ascorbic acid, 1.0166; biotin, 0.00044; vitamin B-12 (0.1% trituration), 0.0297; calcium pantothenate, 0.0661, choline 
dihydrogen citrate, 3.4969; folic acid, 0.00198; inositol, 0.1101; menadione, 0.0495; niacin, 0.0991; pyridoxine HCl, 
0.0220; riboflavin, 0.0220; thiamin HCl, 0.0220; dry retinyl palmitate, 0.0044; dry d,l--tocopheryl acetate, 0.2423; 
corn starch (diluent), 4.6669.
5
 Mineral mixture (TD 79055) obtained from Harlan Teklad (Madison, WI). This mineral mixture is a modification of 
AIN76  lacking calcium, phosphorus, and sucrose as diluent). 
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Table 2
Effects of ovariectomy (Ovx), soy protein devoid of (Soy-), with normal (Soy) and added (Soy+) isoflavones, and 17-estradiol (E2) 
on food consumption, and body and uterus weights
Measure Sham Ovx Ovx+Soy- Ovx + Soy Ovx+Soy+ Ovx+E2 P-Value
Food Intake 15.35±0.30 14.99±0.36 15.10±0.38 14.91±0.36 14.98±0.36 14.87±0.36 0.9757
Body Weights (g)
Initial 312±7 314±8 307±8 312±8 311±8 311±8 0.9920
Final 312±7c      372±8a   359± 8ab 372±7a 350±7b 334±7c <0.0001
Uterus 0.66±0.03a 0.16±0.03c 0.17±0.03c 0.19±0.03c 0.20±0.03c 0.28±0.03b <0.0001
Values are means ± SEM, Values that do not share the same superscript letters are significantly (P<0.05) different from each other; 
n = 12 to 13 rats per group. 
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Table 3
Effects of ovariectomy (Ovx), soy protein devoid of (Soy-), with normal (Soy) and added (Soy+) isoflavones, and 17-estradiol (E2) 
on bone mineral content (BMC) and density (BMD)
Measure Sham Ovx Ovx+Soy- Ovx + Soy Ovx+Soy+ Ovx+E2 P-Value
Whole Body
Before Treatment
BMC (g) 10.61±0.21 10.09±0.23 9.99±0.23 10.24±0.23 10.24±0.23 10.16±0.23 0.9612
BMD (g/cm2) 0.1611±0.002a 0.1569±0.002b 0.1583±0.002 b 0.1610±0.002 b 0.1592±0.002 b 0.1601±0.002 b <0.0001
Final
BMC (g) 10.90±0.18 10.95±0.19 11.06±0.19 11.25±0.18 10.93±0.18 10.81±0.18 0.6415
BMD (g/cm2) 0.1662±0.002a 0.1540±0.002b 0.1527±0.002b 0.1568±0.002b 0.1571±0.002b 0.1582±0.002b 0.0002
Tibia
BMC (g) 0.3583±0.008a 0.3103±0.008c 0.3272±0.008bc 0.3423±0.008ab 0.3296±0.008bc 0.3273±0.008bc 0.0022
BMD (g/cm2) 0.1993±0.002a 0.1825±0.003c 0.1882±0.003bc 0.1908±0.003b 0.1870±0.003bc 0.1892±0.003bc 0.0006
4th Lumbar Vertebra
BMC (g) 0.1279±0.003a 0.1071±0.003b 0.1123±0.003 b 0.1135±0.003 b 0.1116±0.003 b 0.1163±0.003 b 0.0016
BMD (g/cm2) 0.2264±0.003a 0.1986±0.003c 0.2040±0.003bc 0.2041±0.003bc 0.2042±0.003bc 0.2091±0.003b <0.0001
 Values are means ± SEM Values that do not share the same superscript letters are significantly (P<0.05) different from each other; n 
= 12 to 13 rats per group. 
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Fig. 1
Effects of ovariectomy (Ovx), soy protein devoid of (Soy-), with normal (Soy) and added (Soy+) isoflavones, and 17-estradiol (E2) 
on tibial µCT parameters
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Fig. 2. 3-D trabecular images of proximal tibia using micro-CT. (A) Sham, (B) Ovx control, (C) Soy- , (D) Soy, (E) Soy+, and (F) E2
(10 µg 17-estradiol/kg body wt. twice per wk.). Soy-, Soy, and Soy+ contained 0.06, 3.55, and 7.10 mg isoflavones/g protein, 
respectively. In accord with our data, Soy+ had the greatest effect on reversal of trabecular bone structure. 
53
References
[1] Cosman F and Lindsay R. Selective estrogen receptor modulators:  clinical 
spectrum. End Rev 1999;20:418-434.
[2] Setchell KDR. Soy isoflavones--benefits and risks from nature's selective 
estrogen receptor modulator (SERMs). J Am Coll Nutr 2001;20:354S-362S.
[3] Brezinski A and Debi A. Phytoestrogens:  the "natural" selective estrogen 
receptor modulators. Eur J Ob & Gyn & Rep Bio 1999;85:47-51.
[4] Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JWJ. Soy protein 
and isoflavones: their effects on blood lipids and bone density in postmenopausal 
women. Am J Clin Nutr 1998;68 Supp:1375S-1379S.
[5] Dalais FS, Rice GE, Wahlqvist ML, Grehan M, Murkies AL, Medley G, Ayton R, 
Strauss BJG. Effects of dietary phytoestrogens in postemenopausal women. 
Climacteric 1998;1:124-129.
[6] Ho SC, Chan SG, Yi Q, Wong E, Leung PC. Soy intake and the maintenance of 
peak bone mass in Hong Kong Chinese women. J Bone Miner Res 2001;16:1363-
1369.
[7] Gallagher JC, Rafferty K, Haynatzka V, Wilson M. Effects of soy protein on bone 
metabolism. J Nutr 2000;130:667S-
[8] Arjmandi BH, Alekel L, Hollis BW, Amin D, Stacewica-Sapuntzakis M, Gou P. 
Dietary soy protein prevents bone loss in an ovariectomized rat model of 
osteoporosis. J Nutr 1996;126:161-167.
[9] Arjmandi BH, Birnbaum R, Goyal NV, Getlinger MJ, Juma S, Alekel L, Hasler 
CM, Hollis BW, Drum ML, Kukreja SC. Bone-sparing effect of soy protein in 
ovarian hormone deficient rats is related to its isoflavone content. Am J Clin Nutr 
1998;68:1364S-1368S.
[10] Picherit C, Chanteranne B, Bennetau-Pelissero C, Davicco MJ, Lebecque P, 
Barlet JP, Coxam V. Dose-dependent bone-sparing effects of dietary isoflavones 
in the ovariectomized rat. Br J Nutr 2001;85:307-316.
[11] Anderson JJ, Ambrose WW, Garner SC. Biphasic effects of genistein on bone 
tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med 
1998;217:345-350.
[12] Kanis JA. Estrogens, the menopause, and osteoporosis. Bone 1996;19:185S-190S.
[13] Judd HL, Meldrum DR, Deftos LJ, Henderson BE. Estrogen replacement therapy:  
indications and complications. Ann Int Med 1983;98:195-205.
54
[14] Pattijn V, Van Cleynenbreugel T, Vander SJ, Van Audekercke R, Van der PG, 
Wevers M. Structural and radiological parameters for the nondestructive 
characterization of trabecular bone. Ann Biomed Eng 2001;29:1064-1073.
[15] Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. 
Relationship between changes in biochemical markers of bone turnover and BMD 
to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401.
[16] Cummings SR, Bates D, Black D. Clinical use of bone densitometry: scientific 
review. JAMA 2002;288:1889-1897.
[17] Kinney JH, Lane NE, Haupt DL. In vivo, three-dimensional microscopy of 
trabecular bone. J Bone Miner Res 1995;10:264-270.
[18] Mawatari T, Miura H, Higaki H, Kurata K, Moro-oka T, Murakami T, Iwamoto 
Y. Quantitative analysis of three-dimensional complexity and connectivity 
changes in trabecular microarchitecture in relation to aging, menopause, and 
inflammation. J Orthop Sci 1999;4:431-438.
[19] Arjmandi BH, Lucas EA, Juma S, Soliman A, Stoecker BJ, Khalil DA, Smith BJ, 
Wang C. Dried plums prevent ovariectomy-induced bone loss in rats. JANA 
2001;4:50-56.
[20] Gowen M, Lazner F, Dodds R, Kapadia R, Field J, Tavaria M, Bertoncello I, 
Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I. Cathepsin K 
knockout mice develop osteopetrosis due to a deficit in matrix degradation but not 
demineralization. J Bone Miner Res 1999;14:1654-1663.
[21] Arjmandi BH, Khan DA, Juma SS, Svanborg AS. The ovarian hormone 
deficiency-induced hypercholesterolemia is reversed by soy protein and the 
synthetic isoflavone, ipriflavone. Nutr Res 1997;17:885-894.
[22] Blum SC, Heaton SN, Bowman bM, Hegsted M, Miller SC. Dietary soy protein 
maintains some indices of bone mineral density and bone formation in aged 
ovariectomized rats. J Nutr 2003;133:1244-1249.
[23] Tchernof A and Poehlman ET. Effects of the menopause transition on body 
fatness and body fat distribution. Obes Res 1998;6:246-254.
[24] Joyner JM, Hutley LJ, Cameron DP. Estrogen receptors in human preadipocytes. 
Endocrine 2001;15:225-230.
[25] de la Brousse FC, Shan B, Chen JL. Identification of the promoter of the mouse 
obese gene. Proc Natl Acad Sci USA 1996;93:4096-4101.
[26] Sohn E, Deyhim F, Devareddy L, Arjmandi BH. Soy isoflavones attenuate 
estrogen deficiency-induced increases in abdominal fat in the hamster. Nutr Res
2004;24:1023-1029.
55
[27] Arjmandi BH, Getlinger MJ, Goyal NV, Alekel L, Hasler CM, Juma S, Drum 
ML, Kukreja S. The role of soy protein with normal or reduced isoflavone content 
in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin 
Nutr 1998;68:1358S-1363S.
[28] Kalu DN, Liu CC, Hardin RR, Hollis BW. The aged rat model of ovarian 
hormone deficiency bone loss. Endocrinology 1989;126:7-16.
[29] Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone and 
Min 1991;15:175-192.
[30] Barengolts EI, Kouznetsova T, Segalene A, Lathon P, Odvina C, Kukreja SC, 
Unterman TG. Effects of progesterone on serum levels of IGF-1 and on femur 
IGF-1 mRNA in ovariectomized rats. J Bone Miner Res 1996;11:1406-1412.
[31] Kalu DN, Arjmandi BH, Liu C, Salih MA, Birnbaum RS. Effects of ovariectomy 
and estrogen on the serum levels of insulin-like growth factor-I and insulin-like 
growth factor binding protein-3. Bone Miner 1994;25:135-148.
[32] Picherit C, Bennetau-Pelissero C, Chanteranne B, Labecque P, Davicco MJ, 
Barlet JP, Coxam V. Soybean isoflavones dose-dependently reduce bone turnover 
but do not reverse established osteopenia in adult ovariectomized rats. J Nutr 
2001;131:723-728.
[33] Anderson JJB and Garner SC. The effects of phytoestrogens on bone. Nutr Res 
1997;17:1617-1632.
[34] Alekel DL, St Germain A, Peterson CT, Hanson KB, Stewart JW, Toda T. 
Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of 
perimenopausal women. Am J Clin Nutr 2000;72:679-680.
[35] Bouxsein ML. Mechanisms of osteoporosis therapy: a bone strength perspective. 
Clin Cornerstone 2003;Suppl 2:S13-S21.
[36] Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. 
Risedronate preserves trabecular architecture and increases bone strength in 
vertebra of ovariectomized minipigs as measured by three-dimensional 
microcomputed tomography. J Bone Miner Res 2002;17:1139-1147.
[37] Ulrich D, van Rietbergen B, Laib A, Ruegsegger P. The ability of three-
dimensional structural indices to reflect mechanical aspects of trabecular bone. 
Bone 1999;25:55-60.
[38] Muller R, Hannan M, Smith SY, Bauss F. Intermittent ibandronate preserves bone 
quality and bone strength in the lumbar spine after 16 months of treatment in the 
ovariectomized cynomolgus monkey. J Bone Miner Res 2004;19:1787-1796.
[39] Lane NE, Kumer JL, Majumdar S, Khan M, Lotz J, Stevens RE, Klein R, Phelps 
KV. The effects of synthetic conjugated estrogens, a (cenestin) on trabecular bone 
structure and strength in the ovariectomized rat model. Osteoporos Int 
2002;13:816-823.
56
[40] Wronski TJ, Dann LM, Scott KS, Cintrón M. Long-term effects of ovariectomy 
and aging on the rat skeleton. Calcif Tissue Int 1989;45:360-366.
[41] Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowica G, Nahounou M, 
Zhao Q, white DW, Chorev M, Gazit D, Rosenblatt M. Human arathyroid 
hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 
2001;16:1665-1673.
[42] Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska 
BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, 
Marquis RW, Veber D, Gowen M. A potent small molecule, nonpeptide inhibitor 
of Cathepsin K (SB 331750) prevents bone matrix resorption in the 
ovariectomized rat. Bone 2002;30:746-753.
[43] Lark MW, Stroup GB, Dodds RA, Kapadia R, Hoffman SJ, Hwang SM, James 
IE, Lechowska B, Liang X, Rieman DJ, Salyers KL, Ward K, Smith BR, Miller 
WH, Huffman WF, Gowen M. Antagonism of the osteoclast vitronectin receptor 
with an orally active nonpeptide inhibitor prevents cancellous bone loss in the 
ovariectomized rat. J Bone Miner Res 2001;16:319-327.
[44] Laib A, Kumer JL, Majumdar S, Lane NE. The temporal changes of trabecular 
architecture in ovariectomized rats assessed by MicroCT. Osteoporos Int 
2001;12:936-941.
[45] Seeman E. Reduced bone formation and increased bone resorption: rational 
targets for the treatment of osteoporosis. Osteoporos Int 2003;14 Suppl 3:S2-S8.
[46] Barger-Lux MJ and Recker RR. Bone microstructure in osteoporosis: transilial 
biopsy and histomorphometry. Top Magn Reson Imaging 2002;13:297-305.
[47] Kinney JH, Haupt DL, Balooch M, Ladd AJC, Ryaby JT, Lane NE. Three-
dimensional morphomoetry of the L6 vertebra in the ovariectomized rat model of 
osteoporosis:  biomechanical implications. J Bone Miner Res 2000;15:1981-1991.
[48] Fanti O, Monier-Faugere MC, Geng Z, Schmidt J, Morris PE, Cohen D, Malluche 
HH. The phytoestrogen genistein reduces bone loss in short-term overiectomized 
rats. Osteoporos Int 1998;8:274-281.
[49] Choi EM, Suh KS, Kim YS, Choue RW, Koo SJ. Soybean ethanol extract 
increases the function of osteoblastic MC3T3-E1 cells. Phytochemistry 
2001;56:733-739.
[50] Lee YS, Chen X, Anderson JJB. Physiological concentrations of genistein 
stimulate the proliferation and protect against free radical-induced oxidative 
damage of MC3T3-E1 osteoblast-like cells. Nutr Res 2001;21:1287-1298.
[51] Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of insulin-like 
growth factor (IGF) 1, IGF-binding protein (IGFBP) -2, and IGFBP-3 in 
osteoporotic patients with and without spinal fractures. J Bone Miner Res 
1997;12:1272-1279.
57
[52] Devareddy L, Soung D, Khalil DA, Lucas EA, Smith BJ, Arquitt AB, Arjmandi 
B.H. Soy isoflavones may increase bone formation as seen by enhanced 
osteoblast- specific gene products  in ovariectomized rat model of postmenopausal 
osteoporosis. J Bone Min Res 2004;S218:
[53] Gao YH and Yamaguchi M. Suppressive effect of genistein on rat bone 
osteoclasts: involvement of protein kinase inhibition and protein tyrosine 
phosphatase activation. Int J Mol Med 2000;5:261-267.
[54] Gao YH and Yamaguchi M. Suppressive effect of genistein on rat bone 
osteoclasts: apoptosis is induced through Ca2+ signaling. Biol Pharm Bull 
1999;22:805-809.
[55] Amano H, Yamada S, Felix R. Colony-stimulating factor-1 stimulates the fusion 
process in osteoclasts. J Bone Miner Res 1998;13:846-853.
[56] Arjmandi B.H., Khalil DA, Smith BJ, Lucas EA, Juma S, Payton ME, Wild RA. 
Soy protein has a greater effect on bone in postmenopausal women not on 
hormone replacement therapy, as evidenced by reducing bone resorption and 
urinary calcium excretion. J Clin Endocrinol Metab 2003;88: 1048-1054.
58
CHAPTER IV
Fructooligosaccharides enhance the efficacy of soy protein to rebuild bone in 
ovariectomized rats  
Latha Devareddy et al.
aDepartment of Nutritional Sciences and bFood & Agricultural Products Research & 
Technology Center, Oklahoma State University, Stillwater, OK 74078
Corresponding author and reprint requests should be directed to: Bahram H. Arjmandi, 
PhD, RD, Department of Nutritional Sciences, 301 Human Environmental Sciences, 
Stillwater, OK 74078-6141; (405) 744-4437; FAX (405) 744-1357; E-mail: 
arjmand@okstate.edu
Keywords:  Biomechanical properties; Microcomputed tomography;  Isoflavones; 
Ovariectomy 
59
Abstract
Objective: The intestinal microflora is important in rendering soy isoflavones 
bioavailable by facilitating their conversion to equol. Hence, substances that can 
modulate the intestinal microflora could affect the bioavailability of isoflavones.   In this 
study, we examined the effects of fructooligosaccharides (FOS), a prebiotic, on 
enhancing the effects of soy isoflavones on bone in ovariectomized osteopenic female 
rats. 
Design: Sixty three 9-month old female Sprague-Dawley rats were either sham-operated 
(Sham; 1 group) or ovariectomized (Ovx; 4 groups) and were fed control diet for three 
months to induce bone loss. After bone loss was confirmed via dual energy x-ray 
absorptiometry, rats were placed on dietary treatment for 125 days. The Sham and one 
Ovx group received a control diet while the remaining Ovx groups received either a soy 
protein-based diet (Soy), a FOS supplemented diet (FOS), or a soy protein-based and 
FOS supplemented diet (Soy+FOS). Prior to the termination of the study, whole body 
bone mineral density (BMD) and bone mineral content (BMC) were assessed under 
anesthesia. Immediately after euthanasia, bone specimens were collected for the 
assessments of BMD, BMC, biomechanical and microarchitectural properties.
Results: Whole body BMD values were significantly higher in FOS and Soy+FOS 
groups in comparison with Ovx controls. The tibial BMC increased by 10, 6, and 4% in 
Soy, FOS and Soy+FOS groups, respectively when compared to Ovx control group. FOS 
and FOS+Soy treatments had the most pronounced effects in enhancing lumbar BMC and 
BMD. The BMC and BMD were increased in the animals fed FOS diet by 12 and 5.7%, 
respectively when compared to Ovx control groups. The combination of FOS and Soy 
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effectively improved tibial microarchitectural properties by increasing trabecular number 
and decreasing trabecular separation compared to control diet. The effects of dietary 
treatments on lumbar microarchitectural properties were minimal and biomechanical 
properties of the femur were not affected by any of the dietary treatments.
Conclusion: Overall, our findings suggest that the positive bone modulating effects of 
soy can be enhanced in the presence of FOS as seen from the improved BMD and 
microarchitectural properties. The microarchitectural properties of the tibia were 
improved by Soy+FOS treatment as the trabecular number and separation were bought 
back to the level of Sham group.
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Introduction
Osteoporosis is a debilitating disease that affects millions of Americans. It is 
estimated that about one in every two women over the age of 50 years will have an 
osteoporotic fracture in her lifetime.1 Although the US Food and Drug Administration 
(FDA) has approved a number of therapies for the prevention of osteoporosis, there has 
not been a substantial reduction in the incidence of fractures.2 This may be attributed to 
many factors including low compliance, undesirable side effects or high cost of the 
treatment options.2 Recently, there has been an increased interest in the use of alternative 
and complementary medicine for the prevention or treatment of chronic diseases. 
Therefore, an effective alternative/complementary option that can reverse 
postmenopausal bone loss with no or minimal side effects is desirable.
Numerous studies have investigated the osteoprotective role of soy and/or its 
isoflavones in both animals3-5 and humans.6-8 Previously, we have showed that soy 
protein prevents loss of bone due to ovariectomy4 and modestly reverses bone loss in 
osteopenic female rats.9 In contrast to this study9, Picherit et al., 10 indicated that although 
soy isoflavones prevent bone loss, they do not reverse bone loss in Ovx rats. Therefore, 
the findings related to the efficacy of soy and its isoflavones are inconclusive. This may 
be, in part, attributed to the activity of gastrointestinal microorganisms as they influence 
the bioavailability of soy isoflavones.11 An "optimal" gut microflora produces a range of 
metabolites that enhance the bioavilability and absorption of certain nutrients such as 
isoflavones, and other phytochemicals. Although the role of different species of bacteria 
that are responsible for these beneficial activities is not fully understood, bifidobacteria 
and lactobacilli are commonly thought to be the beneficial gut microflora which influence 
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bioavailabilty of nutrients and phytochemicals.12 In this regard, there are a number of 
dietary supplements that can potentially enhance gut microflora including prebiotic 
substances such as fructooligosaccharides (FOS). FOS is a class of indigestible and 
soluble fiber that positively modulates intestinal microflora. For instance, Ohta et al.,13
reported that FOS increases calcium and magnesium absorption in the colon of FOS fed 
rats. FOS has also been shown to augment the effects of soy isoflavones in preventing 
bone loss in ovariectomized rats14 and mice.15 However, to our knowledge the efficacy of 
combining soy and FOS in the reversal of bone loss has not been investigated. The 
objective of the present study was to determine the extent to which soy, FOS and their 
combination reverses ovarian hormone deficiency-induced bone loss. Additionally, the 
effects of these dietary treatments in enhancing biomechanical and microarchitectural 
properties of bone were assessed using three point bending test and microcomputed 
tomography, respectively. 
Materials and methods
Animal care, diets and bone density assessment
Sixty five 9-month old female Sprague-Dawley rats (Harlan; Indianapolis, IN) 
were housed in an environmentally controlled laboratory upon arrival and acclimatized 
for five days. The animals were either ovariectomized (Ovx; 4 groups, N=13) or sham-
operated (Sham; 1 group N=13) and fed AIN-93M (Harlan Teklad; Madison, WI) diet for 
3 months. Rats were pair-fed to the average food intake of Sham group and had free 
access to deionized water. Food intake was recorded every three days and body weights 
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were measured weekly. The composition of the different dietary treatments is presented 
in Table 1. 
Three months from the time of surgery, bone loss was confirmed via dual energy 
x-ray absorptiometry (DXA; QDR-4500A Elite; Hologic, Waltham, MA) and rats in the 
Sham and one Ovx group continued to receive control diet. The remaining Ovx groups 
were assigned to the following treatments: 1) soy protein-based diet (Soy), 2) casein-
based diet plus 5% FOS (FOS) and 3) soy protein-based diet plus 5% w/w FOS 
(Soy+FOS). The proximate analyses of the diets confirmed that they were similar in 
macronutrients, calcium and phosphorus contents. 
All conditions and handling of animals were approved by the Institutional Animal 
Care and Use Committee. At the end of a 125-day treatment period, rats were 
anesthetized with a mixture of ketamine and xylazine (70 mg and 3 mg/kg body weight, 
respectively) to measure whole body BMD and BMC using DXA. Immediately after 
euthanasia, bone specimens were collected.  The BMD and BMC of the tibiae, and 4th
lumbar vertebrae were measured using DXA equipped with appropriate software for bone 
density assessment in small laboratory animals as reported elsewhere.16
Microcomputed tomography (µCT) analysis of tibia and 4th lumbar vertebra
The treatment effect on trabecular structure of the right tibial metaphysis and 4th
lumbar vertebra were evaluated using µCT 40 scanner (Scanco Medical, Switzerland). 
All specimens obtained at sacrifice had been frozen at -20°C until the time of scanning. 
The tibia was scanned from the proximal growth plate in the distal direction (16 
µm/slice). This region included 350 images obtained from each tibia using 1024 x 1024 
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matrix resulting in an isotropic voxel resolution of 22 µm3.17 An integration time of 70 
milliseconds per projection was used, with a rotational step of 0.36 degrees resulting in a 
total acquisition time of 150 minutes/sample. The volume of interest (VOI) was selected 
as a region twenty five slices away from the growth plate at the proximal end of the tibia 
to 125 slices. The 3D images were also obtained for visualization and display.
 Lumbar vertebra were scanned from the caudal to the dorsal end (530 
slices;16µm/slice). This region included 530 images obtained from each vertebra using 
the same isotropic voxel resolution and integration time as described with the tibia. The 
VOI selected 25 slices away from the appearance of the growth plate at each end of the 
vertebral body resulted in approximately 300 slices. Bone morphometric parameters 
including bone volume over total volume (BV/TV), trabecular number (Tb.N.), 
separation (Tb.Sp.), thickness (Tb.Th.), connectivity density, and structure model index 
(SMI) were obtained by analyzing VOI. The operator conducting the scan analysis was 
blinded to the treatments associated with the specimen.
Biomechanical testing of femur
The biomechanical properties of femoral bones were assessed using a three-point 
bending test18 utilizing an Instron Universal Testing Machine (Model 5543; Instron Corp; 
Canton, MA). Each femur was tested in a three-point bending apparatus (TA.XT2i, 
Stable Microsystems, Inc.).  The femur was placed in a three-point bending fixture such 
that the posterior surface rests on the lower supports and the upper support touches the 
anterior surface and the test was performed at a displacement rate of 3 mm/minute.  
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Throughout the test, the anterior surface was under compression and the posterior surface 
is under tension.  The load-displacement curve was recorded simultaneously during the 
test and the ultimate load, yield load and stiffness of the specimen were determined.  
After the mechanical test, the cross-sectional surface at the fracture site was prepared flat 
for tracing and subsequent second moment of area and area calculations.  The ultimate, 
yield stresses, and modulus of elasticity of the specimen were calculated using beam 
bending theory. 19;20
Statistical analyses
The data analysis involved estimation of means and SEM using the Statistical 
Analysis System (SAS) version 8.2 (Cary, NC). Analysis of variance (ANOVA) was 
performed to determine whether there were statistically significant (P < 0.05) differences 
among the groups. When ANOVA indicated any significant differences among the 
means, Fisher’s Least Significant Difference follow-up multiple comparison test was 
used to determine which means were significantly different (P < 0.05). 
Results
Body and organ weights
 Although the food intake was similar among all treatment groups and all of the 
treatment groups started with similar mean body weights (Table 1), at the end of the 
study, the final body weights of rats in the Ovx groups were significantly higher than 
those in the Sham group (Table 2). However, the mean final body weights of animals in 
FOS and Soy+FOS groups were lower than the Ovx controls by 2.7% and 7%, 
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respectively, though difference between Ovx and FOS groups did not reach statistical 
significance. These lower body weight gains in these two treatment groups, in part, can 
be explained by reduced body fat (Table 2). As expected, the mean uterine weight of 
each Ovx group was significantly lower than that of the Sham group (Table 1), indicating 
the success of ovariectomy with neither Soy nor FOS diets imparting estrogen-like effects 
on the uterus.
Bone mineral content and density 
As expected, Ovx control rats had lower whole body BMD than intact rats at the 
end of the three-month treatment period (Table 3).While mean whole body BMD of Soy 
group was somewhat higher than that of Ovx control group, FOS and Soy+FOS treated 
animals had significantly higher whole body BMD values. No effects on whole body 
BMC were observed with any of the treatments.
Tibial BMC was increased in rats in the Soy group by 10.3% to levels similar to 
those of Sham animals. FOS and Soy+FOS were not able to reverse the loss of tibial 
BMC. Soy, FOS and Soy+FOS increased the tibial BMD by 4.5, 3.7 and 3.4%, 
respectively in comparison with Ovx controls, though the values were lower than those of 
rats in the Sham group. Although, all the dietary treatments were able to improve tibial 
BMD, soy treatment had the most pronounced effect on this parameter. 
Ovariectomy resulted in significant losses of lumbar BMC and BMD and FOS 
alone was able to ameliorate these losses. FOS increased lumbar BMC and BMD by 12 
and 5.7%, respectively in comparison with Ovx controls, however, only lumbar BMC 
was brought back to Sham level. In contrast to tibial BMC, Soy and Soy+FOS had lesser 
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effects on lumbar BMC. While soy alone had a minimal effect on lumbar BMD, FOS and 
Soy+FOS were able to significantly increase lumbar BMD (Table 3).
Biomechanical properties of the femur
Data on biomechanical properties of femur are presented in Table 4. Ovariectomy 
did not alter ultimate and yield load, yield stress, or modulus of elasticity. The mean 
femoral stiffness was reduced by 12.6% in untreated Ovx rats when compared to sham 
group. Soy, FOS, and Soy+FOS treatments were all able to increase the stiffness by 
varying degrees with soy treatment reaching a statistical significance. Ultimate stress was 
increased as a result of Ovx , and all of the dietary interventions (FOS, Soy, and 
Soy+FOS) brought this parameter to the Sham level (Table 4). 
µCT Analysis
Figures 1A through 1F show the effects of ovariectomy and dietary treatments on 
microstructural properties of the proximal tibia and 4th lumbar vertebra. As expected, 
ovariectomy decreased BV/TV, connectivity density, and Tb.N and increased SMI and 
Tb.Sp in both tibia and the vertebra. Interestingly, trabecular thickness was increased in 
tibia but not in the vertebra due to ovariectomy. Although none of the treatments could 
reverse the alterations in BV/TV (Fig. 1A) and connectivity density (Fig. 1B), the mean 
vertebral SMI value in Soy+FOS group was not different from either Sham or Ovx 
control group (Fig. 1C). This indicates that Soy+FOS favorably changed trabecular 
morphology from rod- to plate-like structure in the vertebra, however, this change was 
not observed in the tibia. Trabecular number (Fig. 1D) was higher in the Soy+FOS group 
by 17.5 and 10.4% in the tibia and vertebra, respectively in comparison to Ovx controls. 
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FOS also caused an increase in Tb.N., but only lumbar Tb.N. was up to the level of 
Sham. Tibial Tb.Th (Fig. 1E) was increased in the Ovx animals, perhaps to compensate 
for the deterioration of the trabecular microarchitecture, as observed earlier.21 The 
average Tb.Th in Soy+FOS was neither different from that of Sham nor from Ovx control 
group.  Dietary treatment had no effect on lumbar Tb.Th (Fig. 1E). Tibial Tb.Sp. (Fig. 1 
F) was reduced by FOS and Soy+FOS treatments with Soy+FOS having a more 
pronounced effect than FOS alone, as the mean value for Soy+FOS group did not differ 
from Sham. There were no differences in Tb.Sp of the vertebra among the groups. 
Considering all the µCT parameters, the overall results suggest that soy protein in 
combination with FOS may be more efficacious in reversing the loss of trabeculae in 
ovarian hormone deficiency.
Discussion
The higher final mean body weights of the Ovx animals, except for the Soy+FOS
group, were significantly greater than those of Sham animals. This increase in body 
weight is due, in part, to higher body fat. Indeed, the average total body fat of animals in 
Ovx control group was 85% higher than those of Sham animals as determined by DXA. 
In the present study, although Soy or FOS treatment alone were unable to reduce the 
Ovx-induced gains in body weight and fat mass, their combination effectively prevented 
excess body weight and fat mass gains. Our observations are in accord with those of 
Mathey and colleagues14 who reported that FOS enhanced the effects of soy isoflavones 
in preventing body weight gain due to Ovx. Additionally, we postulate that the observed 
effects of FOS on body weight are similar to those observed with other dietary fibers 
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(soluble and insoluble). For instance, a population study by Lissner et al.,22 reported that 
fiber intake was inversely related to obesity rate. Dietary fiber also plays a role in weight 
regulation, by decreasing the rates of gastric emptying and fat absorption.23 In addition to 
the effects of fiber, the intake of soy isoflavones has been shown to attenuate abdominal 
fat gain in Ovx rats24 and postmenopausal women.25 Therefore, it is conceivable that the 
combination of Soy and FOS will have synergistic effects in lowering body weight and 
fat gain as is observed in this study. Accordingly, in the present study Soy plus 5% FOS 
in the diet reversed the Ovx-induced gain in both body weight and adipose tissue. Future 
clinical studies are needed to confirm whether the combination of FOS and isoflavones 
would have a beneficial effect in controlling obesity.
In terms of bone, soy treatment alone significantly increased tibial BMD but had 
no effect on whole body or lumbar BMD. We have previously reported9 the site specific 
action of soy on bone which may be similar to other agents known to augment BMD such 
as estrogen.26 Kinney et al.,26 demonstrated that responses to estrogen were weaker in the 
vertebrae than tibiae. Site specificity of soy isoflavones have also been reported in recent 
studies using rodent models. 14;15 A study by Mathey et al.14 reported that a dose of 40 µg 
isoflavones/g body weight was able to significantly increase diaphyseal BMD of the tibia,
but not the metaphyseal BMD, thereby prevent bone loss due to ovariectomy. In the same 
study, they observed a synergy between isoflavones and FOS. This synergy was credited 
to FOS’s ability to maximize mineral absorption which have been reported by several 
investigators.13;27;28
Although all of the treatments resulted in somewhat improved femoral stiffness, 
only the Soy group had significantly higher mean stiffness than Ovx control group. This 
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finding also agrees with that of Mathey and colleagues14  who reported isoflavone 
treatment enhanced femoral ultimate load stress?, a structural parameter, without 
improving material properties such as yield and modulus of elasticity. FOS did not have 
any synergistic or additive effects on any of the biomechanical properties. We cannot 
offer an explanation for this observation except speculating that when FOS is given along 
with isolated isoflavones bone mineralization is affected; however, bone strength is not 
only dependent on mineral but also on other factors such as bone architecture and matrix 
protein content.29-31 Our observations indicate that soy when combined with FOS was 
effective in reversing the loss of certain trabecular structural parameters in tibia namely 
trabecular number, thickness and separation. Additionally, the combination of soy and 
FOS was able to change the rod-like trabeculae to a more favorable plate-like structure as 
observed from SMI values.   
Several studies have reported the beneficial effects of soy and its isoflavone on 
bone. The findings of the present study indicate that the effects of soy are enhanced by 
FOS. FOS is known to improve calcium and magnesium absorption in rats.32
Nonetheless, this may not be the only way by which FOS modulates bone and mineral 
metabolism. Intestinal calcium malabsoprtion is reported in both postmenopausal 
women33 and Ovx rats 34 and is believed to aggravate negative calcium balance and 
contribute to bone loss.33;35-37 This, in part, can be abated by FOS as it enhances calcium 
absorption. Relevant to the present study, FOS also enhances the bioavailabilty of 
isoflavones as it increases the hydrolysis of glyconated isoflavones to aglycones, the 
active form. Equol is a metabolite of an isoflavone, diadzein, that is formed by intestinal 
microflora in humans.38 Several studies15;39 have shown that FOS is a prebiotic that 
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enhances this favorable bacterial proliferation and increases bacterial -glucosidase 
activity, an enzyme that cleaves isoflavones to produce its aglycones and metabolites. In 
summary, FOS enhances the bone modulating effects of soy enough to reverse bone loss 
due to ovariectomy. Future studies should illustrate the mechanisms by which the 
beneficial effects of these two components are exerted on bone. 
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Table 1
Composition of diets 
Ingredient Control Diet 
(g/100g)
FOS Diet 
(g/100g)
Soy+FOS Diet
(g/100g)
Soy protein (normal isoflavones)1 22.70
Casein2 22.70 22.70 -
Corn Starch 20.00 20.00 20.00
Sucrose 41.76 36.76 36.76
FOS3 - 5.00 5.00
Cellulose4 5.60 5.60 5.60
Corn Oil 5.70 5.70 5.70
Mineral mix, Ca-P deficient (TD 79055)5 1.34 1.34 1.34
Vitamin mix (TD 40060)6 1.0 1.0 1.0
Calcium carbonate CaCO3 1.16 1.16 1.03
Sodium phosphate monobasic 
NaH2PO4.H2O
0.388 0.388 0.388
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Potassium Phosphate Monobasic KH2PO4 0.238 0.238 0.238
Potassium citrate monohydrate 0.090 0.090 0.090
1
 Soy protein isolate obtained from The Solae Company (St. Louis, MO).
2
 Teklad diet #88190 (Harlan Teklad, Madison, WI).
3
 Kirkman Laboratories, Inc (Lake Oswega, OR)
4Alphacel obtained from ICN Biochemicals (Costa Mesa, CA).
5Mineral mixture (TD 79055) obtained from Harlan Teklad (Madison, WI). This mineral mixture is a modification of AIN 76 lacking 
calcium, phosphorus, and sucrose as diluent). 
6Vitamin mixture (g/kg diet; TD 40060) obtained from Harlan Teklad (Madison, WI):  p-aminobenzoic acid, 0.1101; ascorbic acid, 
1.0166; biotin, 0.00044; vitamin B-12 (0.1% trituration), 0.0297; calcium pantothenate, 0.0661, choline dihydrogen citrate, 3.4969; 
folic acid, 0.00198; inositol, 0.1101; menadione, 0.0495; niacin, 0.0991; pyridoxine HCl, 0.0220; riboflavin, 0.0220; thiamin HCl, 
0.0220; dry retinyl palmitate, 0.0044; dry d,l--tocopheryl acetate, 0.2423; corn starch (diluent), 4.6669.
74
Table 2
Effects of ovariectomy (Ovx), soy with isoflavones (Soy), fructooligosacchrides (FOS) and their combination (Soy+FOS) on food 
consumption, and body and uterus weights
Measure Sham Ovx Soy FOS Soy+FOS P-Value
Food Intake 15.35±0.30 14.99±0.36 15.10±0.35 14.98±0.35 15.01±0.36 0.9850
Body Weights (g)
Initial 312 ± 7 314 ± 8 311 ± 7 315 ± 8 311 ± 7 0.9938
Final 320 ± 7c      372 ± 8a 372 ± 6a 362 ± 6
ab 346 ± 6b <0.0001
Final Fat Mass (g) 69±7c 128±8a 113±8ab 105±8b 85±8c <0.0001
Uterus 0.66±0.03a 0.16±0.04b 0.19 ±0.04b 0.16 ± 0.04
b 0.18 ± 0.04b <0.0001
Values are means ± SEM, Values that do not share the same superscript letters are significantly (P<0.05) different from each other; 
n = 13 rats per group. 
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Table 3
Effects of ovariectomy (Ovx), soy with isoflavones (Soy), fructooligosacchrides (FOS) and their combination (Soy+FOS) on bone 
mineral content (BMC) and density (BMD)
Measure Sham Ovx Soy FOS Soy+FOS P-Value
Whole Body
Before Treatment
BMC (g) 10.76 ± 0.20 10.73 ± 0.20 10.87 ± 0.20 10.86 ± 0.20 10.55 ± 0.20 0.7811
BMD (g/cm2) 0.1704 ± 0.002a 0.1564 ± 0.002b 0.1597 ±0.002b 0.1605 ±0.002b 0.1583 ± 0.002b <0.0001
Final
BMC (g) 10.90 ± 0.19 10.94 ± 0.20 11.23 ± 0.20 11.39 ± 0.20 10.85 ± 0.19 0.2187
BMD (g/cm2) 0.1663 ± 0.002a 0.1540 ± 0.002c 0.1568 ± 0.002bc 0.1613 ± 0.002b 0.1590 ± 0.002b 0.0002
Tibia
BMC (g) 0.3584 ± 0.007a 0.3102 ± 0.008c 0.3423 ± 0.008ab 0.3269 ± 0.008bc 0.3221± 0.008bc 0.0005
BMD (g/cm2) 0.1993 ± 0.002a 0.1825 ± 0.002c 0.1908 ± 0.002b 0.1892 ± 0.002b 0.1887 ± 0.002b <0.0001
4th Lumbar Vertebra
BMC (g) 0.1279 ± 0.004a 0.1071 ± 0.004c 0.1135 ± 0.004bc 0.1200 ± 0.003ab 0.1147 ± 0.003bc 0.0013
BMD (g/cm2) 0.2264 ± 0.003a 0.1986 ± 0.003c 0.2046 ± 0.003bc 0.2100 ± 0.003b 0.2088 ± 0.003b <0.0001
Values are means ± SEM Values that do not share the same superscript letters are significantly (P<0.05) different from each other; n = 
13 rats per group.
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Table 4
Effects of ovariectomy (Ovx), soy with isoflavones (Soy), fructooligosacchrides (FOS) and their combination (Soy+FOS) on 
Biomechanical Properties of Femur
Measures Sham Ovx Soy FOS Soy+FOS P-Value
Femur
Ultimate Load (N) 69.23 ± 0.24 69.37 ± 0.27 69.04 ± 0.26 69.62 ± 0.26 69.90 ± 0.30 0.3255
Yield Load (N) 85.56 ± 5 80.28  ± 6 76.66 ± 6 85.23  ± 5 85.22 ± 5 0.7231
Stiffness (N/mm) 143 ± 3.69a 125 ± 1.46c 138 ± 3.98ab 133± 3.98abc 134 ± 3.98abc 0.0370
Ultimate Stress  
(N/mm2)
96 ± 6b 122±7a 93±7b 98±6b 101±7b 0.0173
Yield Stress (N/mm2) 118 ± 10 137 ± 14 106 ± 12 119 ± 9 120 ± 9 0.5384
  Modulus Elasticity 
(N/mm2)
4034 ± 287 4649 ± 324 3644 ± 315 3767 ± 310 4000 ± 310 0.2315
Values are means ± SEM Values that do not share the same superscript letters are significantly (P<0.05) different from each other; n 
= 13 rats per group.
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Fig. 1
Effects of ovariectomy (Ovx), soy with isoflavones (Soy), fructooligosacchrides (FOS) and their combination (Soy+FOS) on tibial and 
lumbar microarchotectural properties
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CHAPTER V
SUMMARY AND CONCLUSIONS 
Summary
The objective of this research was to evaluate the dose-dependent effects of soy 
isoflavones in the reversal of bone loss as assessed by bone mineral content, bone mineral 
density, biomechanical and microarchitectural properties of bone in an ovariectomized rat 
model of postmenopausal osteoporosis. Additionally, the synergistic role of the 
combination of soy isoflavones and fructooligosacharides FOS in the reversal of bone 
loss was also evaluated by assessing BMC, BMD, bone biomechanical and 
microarchitectural properties.
The research objectives, hypotheses and the specific aims of the study are listed in 
Chapter I of this dissertation. The central hypothesis of this study was that soy protein 
with its isoflavones reverses bone loss in an ovariectomized (Ovx) rat model of 
postmenopausal osteoporosis. The ancillary hypothesis of this study was that soy 
isoflavones and FOS exert synergistic effects in the reversal of bone loss in osteopenic 
ovx rats.
The review of literature that is pertinent to the objectives of this study, which 
includes review on general bone structure and biology; systemic and local factors of bone
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 metabolism; estrogen and bone; prevalence; etiology; therapies for postmenopausal 
osteoporosis;  soy and bone health; and FOS health benefits.
Chapter III includes methods, results and discussion addressing the central 
hypothesis. Although there have been numerous studies examining the role of soy 
isoflavones in enhancing bone health, to our knowledge there are no studies examining 
the effects of soy isoflavones in reversing the loss of microarchitectural properties. 
In terms of body weight gain, as expected ovariectomy resulted in a significant 
(P<0.05) increase in body weight and this was completely prevented by estrogen.  Soy
with added isoflavones modestly prevented the body weight gain, however, Soy and Soy-
had no such effects on body weight. 
Ovariectomy resulted in significant loss of whole body, tibial and lumbar BMD. 
While none of the dietary treatments had any effect on whole body BMD, Soy was able 
to increase the tibial BMC and BMD by 10.3% and 4.5% when compared to Ovx 
controls. Soy-, Soy+ and E2 did not reverse the loss of tibial BMD. The soy treatments 
increased the lumbar BMD values numerically, but not significantly. 
In the present study, microCT data indicated that Ovx caused a deterioration of 
trabecular microarchitecture as seen from decreased BV/TV, Tb.N., CD, and increased 
Tb.Th. Ovariectomy also resulted in change of trabecular morphology from plate- to 
more inferior rod-like structures. The dietary treatments were not able to improve 
BV/TV, CD, SMI, or Tb.Th. of both the tibia and the vertebra. Soy with added 
isoflavones was able to restore the Tb.N. and decrease Tb.Sp. in the tibia, however, the 
effects of soy were less pronounced in the lumbar vertebra.
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The findings of this study indicate that soy protein with normal isoflavone levels 
has a biphasic and site specific effect on the reversal of bone loss, whereas higher doses 
of isoflavones may be required to reverse the loss of microarchitectural properties. 
Chapter IV addressed the ancillary hypothesis of this study. The objectives of the 
study were to determine the extent to which soy, FOS and their combination reverses 
ovarian hormone deficiency-induced bone loss. Additionally, the effects if these dietary 
treatments of microarchitectural and biomechanical properties were evaluated.
Soy+FOS treatment was somewhat able to prevent ovariectomy-induced gain in 
body weight. These lower body weight gains in this two treatment groups, in part, can be 
explained by reduced body fat. The low uterine weight in the Ovx groups indicated the 
success of ovariectomy and that neither Soy nor FOS diets imparted estrogen-like effects 
on uterus.
In terms of bone, FOS and Soy+FOS treatments had the most pronounced effects 
on whole body BMD as the means of these two groups were significantly (P<0.05) 
higher that Ovx controls. No effects on whole body BMC were observed with any of the 
treatments. Though soy protein with normal levels of isoflavones was able to restore the 
loss of tibial BMC, FOS and Soy+FOS treatment were unable to reverse the loss of tibial 
BMC. Soy, FOS and Soy+FOS increased the tibial BMD by 4.5, 3.7 and 3.4%, 
respectively in comparison with Ovx controls, albeit the values were lower than those of 
rats in the Sham group. Although, all the dietary treatments were able to improve tibial 
BMD, soy treatment had the most pronounced effects. The Ovx-induced loss of lumbar 
BMC was ameliorated only by FOS. Ovariectomy resulted in significant losses of lumbar 
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BMC and BMD and FOS alone was able to ameliorate these losses. Soy and Soy+FOS 
had intermediary effects on the reversal of lumbar BMD. 
Ovariectomy did not alter ultimate and yield load, yield stress, or modulus of 
elasticity, however, femoral stiffness was reduced by Ovx rats. Soy, FOS, and Soy+FOS 
treatments were all able to increase the stiffness by varying degrees with soy treatment 
reaching a statistical significance. Ultimate stress was increased as a result of Ovx , and 
all of the dietary interventions (FOS, Soy, and Soy+FOS) brought this parameter to the 
Sham level. 
The combination of soy and FOS had the most pronounced effects in reversing 
the loss of tibial and lumbar microarchitectural properties. Soy+FOS group was able to 
somewhat restore the ratio of rods and plates of the trabecular bone to an increased 
proportion of plates than the Ovx control group in the vertebra, however, this change was 
not observed in the tibia. Similarly, Soy+FOS treatment significantly increased Tb.N. in 
the tibia and vertebra. FOS also caused an increase in Tb.N., but only lumbar Tb.N. was 
up to the level of Sham. Tibial Tb.Th. in Soy+FOS was neither different from that of 
Sham nor from Ovx control group, whereas in the vertebra, dietary treatments had no 
effect on lumbar Tb.Th. or Tb.Sp. Tibial Tb.Sp. was reduced by FOS and Soy+FOS 
treatments with Soy+FOS having a more pronounced effect than FOS alone. In summary, 
the overall results of the microarchitectural properties indicated that  soy protein in 
combination with FOS may be more efficacious in reversing the loss of trabeculae in 
ovarian hormone deficiency.
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Conclusions
Based on the results of the experiment 1, soy protein and its isoflavones appear to 
have a modest beneficial effect in established osteoporosis as evident by improvements in 
tibial BMC and BMD and certain structural parameters. Interestingly, in the present study 
we found that while too little or too much isoflavones may not have any effect on tibial 
BMD, higher doses of isoflavones may be required to reverse the loss of tibial 
microstructural properties. Nonetheless, it is too early to conclude that soy protein or its 
isoflavones should be supplemented to prevent or reverse bone loss induced by ovarian 
hormone deficiency.
In experiment 2, the results indicated that the positive bone modulating effects of 
soy are further augmented by the addition of FOS as seen from the improved BMD and 
microarchitectural properties.  Soy when combined with FOS was effective in reversing 
the loss of certain trabecular structural parameters in tibia namely trabecular number, 
thickness, and separation. The combination of soy and FOS was also able to change the 
rod-like trabeculae to a more favorable plate-like structures as observed from SMI values.
The mechanisms by which the combination of Soy and FOS enhance bone quality need to 
be elucidated. 
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